NEWEST ← 12  11  10  9  8  7  6  5  4  3  2  1  → OLDEST

Tritha Electric – An Indo-French Musical Treat in your city
~Rock band to perform next in Chandigarh, Dehradun &Thiruvananthapuram~

31th March 2018: Tritha Electric, an Indo-French fusion band, after touring 16 countries, is currently on a nationwide ALLIANCE FRANÇAISE TOUR in India where they are touring 8 cities for concerts that are being held to celebrate the International Francophonie Week. The band’s distinctive music is inspired by German Krautrock of the 1970s and Indian folk melodies that mixes classical music with psychedelic rock that created a unique mix that has connected very well with audiences.

After touring more than 16 countries, the band is currently touring India. After successful concerts in New Delhi, Bhopal and Chennai last week, Tritha Electric is all set to perform in North India with Chandigarh being first on the list on 31st March 2018, followed by Dehradun on 2nd April 2018. The band will also perform in Trivandrum on 4th April 2018.

Tritha’s first album, PaGLi released in 2014. PaGLi, which literally translates to ‘Mad Woman’, aptly described the songs in the album. Fish Market, a track with chaos and eccentricity, much like its album name, was one of the album tracks that gained quick popularity. The release of the album saw the band take off on an 18-month tour which saw the band perform over 100 shows across three continents, it is at this point that the trio became officially known as Tritha Electric.

The band released their debut album Raagas in Paris on Indian label Silk Road in 2017. Raagas in Paris was named because of the band recording the songs at a studio in Paris. The album, unlike its predecessor, does not feature the mayhem of the above-mentioned songs from PaGLi. Moreso, it brings out a calmer, subdued side to Tritha’s voice. Other than Bong Voyage, which took Sebastien Cotheillas on board, all songs in the album have been composed by Tritha, Paul Schneiter and Mathew Durand.

The band’s performances focuses on the themes of freedom, women empowerment, and social and environmental consciousness combined with lyrics involving ancient classical raagas and folk compositions. Much of their songs’ distinct German Krautrock style can be credited to Mathias’ flamboyant style of playing his electric guitar. Rangamati, a fan favourite, released in August 2016 as a music video and gathered more than 50,000 single views in the first week following its release.

Notably, all lyrics have been written by Tritha Sinha, except Yaman Rhapsody which consists of two classical compositions dated many centuries back by an anonymous author possibly in the 15-16th century and Radha’s Fantasy which has some words taken from a Baul folk song KolonkiniRadha.

Tritha Electric was started by classical vocalist Tritha Sinha and drummer/producer Paul Schneiter in 2010. Known for its unique music and equally quirky album names, Tritha Electric gained quite a fan base in Europe and Africa where the rock music drew the audience attention and Tritha’s classical notes mesmerised. The band attained musical maturity when Mathias Durand, a guitar and piano virtuoso equally at ease with Western and Indian classical music, joined the band in 2012.


Chandigarh                     – 31st March 2018, Alliance Francaise De, Next to Hibiscus Garden

Dehradun                         – 2nd April 2018, Graphic Era University (Clement Town)

Thiruvananthapuram – 4th April 2018, Bharat Bhavan

Mumbai                             – 6th April 2018, TBC

Kolkata                              – 08thApril 2018, Allen Park

More about Tritha Electric:

Press Kit:

Listen on Saavn:

Listen on Apple Music:


Ras Al Khaimah to host OTOAI’s 17th annual conference

Outbound Tour Operators Association of India (OTOAI) is organising its 17thannual conference in Ras Al Khaimah. Around 170 travel partners from India will participate in this annual conference,which is going to take place from September 12-14, 2017.

OTOAI is a national, not-for-profit organisation comprising India’s outbound tour operators and travel agents as its members. A Memorandum of Understanding (MoU) was signed byHaitham Mattar, CEO of Ras Al Khaimah Tourism Development Authority and Guldeep Singh Sahani, President of OTOAI, during the press conference held in Delhi in April, 2015.

Mattaris very hopeful of the convention. He says,“India is currently our fourth largest international source market with year-on-year growth of 22 per cent in the first half of 2017. It will be an important contributor to our vision and Destination 2019 tourism strategy. We have seen a growing trend from Indian inbound tourism for short leisure stays, MICE, and weddings. Our aim is to promote the full breadth of unique activities and events that can be enjoyed in the emirate, with a view to encourage Indian travellers to lengthen their stay in the destination. We are optimistic that through focused efforts and participation in various MICE and trade events, tourism from India will continue to develop in the coming years.”

The emirate of Ras Al Khaimah is still largely unexplored. OTOAI’s annual conference will present an opportunity to travel partners to meet many potential sellers from Ras Al Khaimah, like Waldorf Astoria, Hilton Hotels, Sky Max Holidays, and Desert Adventures who will be a part of this prestigious event.

QIAGEN and Clinical Genomics Partner on Liquid Biopsies to Monitor Patients for Recurrence of Colorectal Cancer

QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) and Clinical Genomics, a private company developing evidence-based diagnostic tools for colorectal cancer, today announced they have implemented the PAXgene® Blood ccfDNA Tube* sample collection in Clinical Genomics’ Colvera™ colorectal cancer (“CRC”) recurrence assay. Colvera, an integrated liquid biopsy solution, is designed to enable easy and accurate monitoring for recurrence of colorectal cancer with a simple blood test collected in a physician’s office.

“The Colvera test represents a unique opportunity for convenient, non-invasive monitoring of colorectal cancer patients by detecting methylated circulating tumor DNA that may indicate recurrence of a cancer. We are pleased to collaborate with Clinical Genomics in expanding the range of benefits made possible through liquid biopsies, which hold great promise for improving the lives of patients in cancer and other fields of medicine,” said Thierry Bernard, Senior Vice President and Head of QIAGEN’s Molecular Diagnostics Business Area.

“We are extremely pleased to use the highly automated QIAsymphony PAXgene Blood ccfDNA collection and sample processing workflow for collection and handling of Colvera samples. As a long-term commercial and research partner of QIAGEN, we have a great deal of confidence in this new solution,” said Dr. Lawrence LaPointe, CEO of Clinical Genomics. “We are excited to roll out the PAXgene System as the front-end solution to allow physicians to provide Colvera testing to CRC patients as conveniently as possible. PAXgene allows a simple blood collection at the physician’s office, with no on-site processing required, which is a great step forward from our alternative sample collection methods.”

Click here for the full press release

Investor Relations
John Gilardi

Public Relations
Dr. Thomas Theuringer
+49-2103- 291-1826

Patty Jenkins

Fleet Complete, First Among Telematics Service Providers to Join Blockchain in Trucking Alliance (BiTA)

Global commercial vehicle IoT solutions provider joins the alliance of commercial vehicle eco-system partners to advance the adoption of Blockchain in trucking.

Fleet Complete has joined Blockchain in Trucking Alliance (BiTA) – a consortium for the adoption, education and development of a standard framework around Blockchain in the trucking industry – as a service charter member. The consortium comprises a diverse group of partners that will work together to establish best practices and protocols around Blockchain applications. The group will also work towards educating the market and encourage Blockchain use in the trucking industry.

Fleet Complete echoes BiTA’s belief that Blockchain is one of the biggest technological developments for the future of the freight transportation industry, delivering self-executing transactions to liberate accounting systems and create transparency for all parties involved. With Blockchain-capable transactions, the trucking industry will gain several benefits, such as immediate payments to drivers upon delivery, self-directing fuel and maintenance payments, complete automated settlements, and infinite recording of carrier history and safety.

“Joining BiTA was a natural decision for us,” comments Tony Lourakis, CEO of Fleet Complete. “We are passionate about making complicated business operations simple and easy for our customers through innovative technologies and industry leading customer support. BiTA’s goal to facilitate the adoption of Blockchain transactions in trucking coincides with our objectives. We believe our customers and partners will benefit from this collaboration, which will bring powerful fleet management innovations.”

The global commercial vehicle industry is transitioning from a product-based business model to the one that relies on customer-focused services and solutions for growth. Enabled by digitization, this transition is disrupting and transforming all corners of the industry, where innovative use of technology, such as Blockchain, creates unique opportunities as well as challenges for the trucking industry stakeholders. With BiTA engaging the best minds in the transportation, finance, and technology sectors, the development of comprehensive standards is afoot to ensure smooth, effective, and efficient adoption of this transactional technology.

“We are thrilled that Fleet Complete has joined BiTA to help develop industry standards that global telematics and transportation technology companies will use for decades to come. Mobile IoT adoption of Blockchain standards is a major step in ushering in the world of self-executing smart contracts in the logistics and freight industries. Fleet Complete’s leadership in the telematics space will help to set the market standard for Blockchain in trucking,” states Craig Fuller, Co-Founder of BiTA.

Founding partners of this alliance include organizations such as McLeod Software, Triumph Business Capital, U.S. Xpress, Convoy, 10-4 Systems, and TransRisk, among others. Joining these industry leaders, Fleet Complete will bring unparalleled global expertise in telematics, mission-critical mobile resource management, and IoT communications to enable the creation of governing principles for the Blockchain’s adoption in trucking.

Over the past two decades, Fleet Complete has been heavily invested in the advancement of its comprehensive IoT platform, planning for the future needs and business growth of its clients worldwide. The company has built a value-based business model, offering fleets and mobile workforces mission-critical telematics services and solutions that enable its global client partners and customers to not only reduce significant costs but also create efficiency and bigger income opportunities. Today, Fleet Complete takes yet another leap to be at the forefront of the digitized trucking industry.

About Fleet Complete® 
Fleet Complete® is a leading global IoT provider of mission-critical fleet, asset, and mobile workforce management solutions. Since 2000, Fleet Complete has been providing mobile resource management solutions to more than 8,000 businesses and 250,000 subscribers worldwide. The company maintains key distribution partnerships with AT&T in the U.S., TELUS in Canada, Telstra in Australia and T-Mobile in Europe, remaining one of the fastest-growing companies in North Americathat has won numerous awards for innovation and growth.

For more information, please visit

About Blockchain in Trucking Alliance
Founded in August 2017, the Blockchain in Trucking Alliance (BiTA) is a forum for promotion, education, and encouragement to develop and adopt Blockchain applications in the trucking, transportation, and logistics industries. BiTA’s members are to participate, discuss, create, and adopt industry standard uses of Blockchain applications, providing clarity and direction for the development of Blockchain technology in the trucking industry in a manner that will create efficiency, transparency, and foster trust.

For more information, visit

David Prusinski, EVP, Sales and Marketing, Fleet Complete,

SOURCE Fleet Complete

Meridian Mining Completes Continuation to UK

Meridian Mining SE (TSX V: MNO) (“Meridian” or the “Company”) today is pleased to announce that it has relocated its head office from Amsterdam, the Netherlands to London, United Kingdom (“UK”). The UK Corporate Registry has finalized the continuation and the Company is now governed by the laws of the United Kingdom. Shareholders approved the continuation at the Company’s Annual General Meeting held in Amsterdam, the Netherlands, on June 29, 2017.

Concurrently with the continuation, the Company announces changes to its Board of Directors (the “Board”).  Alister Hume, an investment manager with the Sentient Fund and based in London, UK, was appointed  as a non-executive director to the Board. Mr. Hume established the Sentient UK office in 2013 to manage a number of mining investments within the Sentient portfolio. Prior to joining Sentient Mr. Hume worked at RBS Morgan’s in an Investment Advisor role with a focus on metals and mining. Mr. Hume holds a bachelor’s degree in Commerce from the University of Sydney

In addition, Angelina Mehta and Stefano Haver have stepped down from their roles on the Board. Meridian would like to thank Ms. Mehta and Mr. Haver for their valuable contribution to the Company and wish them all the best in their future ventures.

On behalf of the Board of Directors of
Meridian Mining SE

“Anthony Julien”
Anthony Julien
President, CEO and Director


Meridian Mining SE is focused on the acquisition, exploration, development and mining activities in Brazil. The Company is currently focused on exploring and developing the Espigão manganese project, the Bom Futuro tin JV area, and adjacent areas in the state of Rondônia. The Company employs a two-pronged strategy with the objective of growing pilot production while advancing a parallel multi-commodity regional exploration program. Meridian is currently producing high grade manganese at its project located at Espigão do Oeste.

Further information can be found at

Some statements in this news release contain forward-looking information or forward-looking statements for the purposes of applicable securities laws. These statements include, among others, statements with respect to the Company’s plans for exploration and development of its properties and potential mineralization. These statements address future events and conditions and, as such, involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the statements. Such risk factors include, among others, failure to obtain regulatory approvals, failure to complete anticipated transactions, the timing and success of future exploration and development activities, exploration and development risks, title matters, inability to obtain any required third party consents, operating hazards, metal prices, political and economic factors, competitive factors, general economic conditions, relationships with strategic partners, governmental regulation and supervision, seasonality, technological change, industry practices and one-time events. In making the forward-looking statements, the Company has applied several material assumptions including, but not limited to, the assumptions that: (1) the proposed exploration and development of mineral projects will proceed as planned; (2) market fundamentals will result in sustained metals and minerals prices and (3) any additional financing needed will be available on reasonable terms. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise except as otherwise required by applicable securities legislation.

The TSX Venture Exchange has in no way passed upon the merits of the proposed Arrangement and has neither approved nor disapproved the contents of this news release.  Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE Meridian Mining S.E.

CONTACT: For more information please contact visit the Company’s website at or contact: Fiona Grant Leydier, 416-848-9851,

Asetek Collaborates with Lenovo on Liquid Cooled Lenovo Legion Y920 Tower

Asetek® (ASETEK.OL) announced today that it is collaborating with Lenovo® to cool its new Lenovo Legion™ Y920 Tower. Designed for gamers, the new Lenovo Legion Y920 Tower offers everything you would expect from one of the world’s top PC manufacturers, allowing gamers to test their abilities and not the limits of their rig.

“It is a pleasure to collaborate with Lenovo,” said John Hamill, Asetek Chief Operating Officer. “The Lenovo Legion Y920 Tower combines a high-performance PC gaming design with the reliable and whisper quiet performance of Asetek liquid cooling.”

“Lenovo is committed to bringing gamers the best performance and most immersive PC gaming experiences,” said Will Fu, Director of Gaming Business, Lenovo PCs and Smart Devices. “For those looking for a leg up in their gaming, Asetek liquid cooling provides that extra edge.”

In EMEA, the Lenovo Legion Y920 Tower with optional integrated liquid cooling will be available on starting at €2,399 (VAT included) in October 2017.1

Specs for the Lenovo Legion Y920 Tower can be found here.

Factory filled and sealed for maximum reliability and ease-of-use, Asetek’s patented liquid coolers have been thoroughly tested and certified to operate without maintenance. Learn more about Asetek technology at

1 Prices may not include tax and does not include shipping or options and are subject to change without notice; additional terms and conditions apply. Reseller prices may vary. On-shelf dates may vary by geography and products may only be available in selected markets. All offers subject to availability. Lenovo reserves the right to alter product offerings, features and specifications at any time without notice.

LENOVO and LENOVO LEGION are trademarks of Lenovo.

About Asetek

Asetek is the global leader in liquid cooling solutions for data centers, servers and PCs. Founded in 2000, Asetek is headquartered in Denmark and has operations in CaliforniaTexasChina and Taiwan. Asetek is listed on the Oslo Stock Exchange (ASETEK). For more information, visit

Media Contact:

Zack Fanning

Asetek Marketing Communications Manager


This information was brought to you by Cision,c2330555


Asetek Selected by Lenovo to Cool New Legion Y920 Tower Desktop Gaming PC

Asetek® announced today that it is collaborating with Lenovo® to cool its new Legion™ Y920 Tower desktop gaming PC.

For the full press release go to Link.

About Asetek

Asetek is the global leader in liquid cooling solutions for data centers, servers and PCs. Founded in 2000, Asetek is headquartered in Denmark and has operations in CaliforniaTexasChina and Taiwan. Asetek is listed on the Oslo Stock Exchange (ASETEK.OL).

For questions or further information, please contact:


CEO and Founder André S. Eriksen, +45-2125-7076, email:

This information was brought to you by Cision,c2330568

The following files are available for download:


Asian-American Media Leaders Launch World’s First K-Beauty Social Network At KCON

South Korean exports have ignited a global craze, and among those exports, Korean cosmetics—commonly known as K-beauty—are among the most popular and profitable, with US sales hitting $225M in 2016.

In response to the rise of K-beauty, tech entrepreneur James Sun has assembled a team of Asian-American media leaders and influencers to launch the world’s first K-beauty-focused social network at The W2Beauty social network is fully integrated with an editorial and shopping site, which utilizes a Seoul-based direct sourcing and fulfillment team to identify and provide cult items, trending products, and major new releases to global consumers.

Sun says, “As a Korean-American, I’ve had a desire to bridge the creative talents, culture, and products from Korea to the rest of the world. Korean dramas and Korean beauty are a natural extension of this global phenomenon.”

International K-beauty fans’ hunger for community is apparent on social media. According to consulting group, Instagram users created 15 million posts about K-beauty between 2014 and 2016, with K-beauty Instagram posts having received over 500M social interactions.

Until now, however, users have been segregated among generic platforms like Instagram, Facebook, and Reddit. Seeing the success of other subject matter-focused communities, like Twitch and the wine lovers’ social network Vivino, as well as his own K-drama site, which boasts over 14M users in the past 12 months, Sun set out to provide a similar platform for K-beauty fans to engage in peer-to-peer interactions.

To support the community with expert educational content, Sun assembled an editorial team and “K-Beauty Squad,” featuring leaders from Asian-American and beauty media. The team is led by editor in chief Anna M. Park, former EIC of Audrey magazine, and top English-language K-beauty blogger Jude Chao as editor at large. Other contributing editors include Coco Park, author of Korean Beauty Secrets: A Practical Guide to Cutting-Edge Skincare and Makeup, K-beauty influencer Sheryll Donerson, as well as an array of leading beauty vloggers.

Sun says, “K-beauty is not only for Asians or Koreans. In fact, the right K-beauty products can be perfect for skin types all around the world. Our team of writers and influencers are Asian, Latina, African American, and we have customers from the Middle East to Latin America to Australia.”

The first wave of K-Beauty in the global market was heavily focused on retail and ecommerce. Sun and his team envision their comprehensive social shopping community as K-beauty 2.0.

Jude Chao, W2Beauty

About W2Beauty

Launched in 2017, W2Beauty is the one-stop destination for everything K-beauty with community, shopping, and editorials. W2Beauty is a US-based company with a direct sourcing team located in South Korea, enabling customers to enjoy the credibility, service, and trust of a US company with the true insider access and expertise of the Korean team.


SOURCE W2Beauty Acquires

The media company behind gaming industry news portal has acquired cryptocurrency news site as part of site founder Calvin Ayre’s deeper involvement in all things Bitcoin. was set up to address fake news in the gaming industry and’s clear intent to do the same in the Bitcoin world has impressed both Calvin himself and the team behind With the established financial system putting its might behind derailing Bitcoin, alarmist and inaccurate media in the space is, sadly, rife.

The plan is for to continue to cover Bitcoin news as it relates to the gaming industry, while using its considerable resources to enable to hire more technical and media personnel, thereby allowing the site to provide truly global coverage of this rapidly expanding economic instrument.

Many governments are looking into Bitcoin with economic heavyweight, Japan, taking the step to officially recognise the cryptocurrency. Antigua & Barbuda are also looking to take a lead in Bitcoin-related commerce, having recently named Calvin Ayre as their specific economic envoy for Bitcoin and blockchain technology.

Mr Ayre is personally putting his time, effort and financial resources into projects that expand Bitcoin’s reach and acceptance. Ayre maintains that massive on-chain scaling is needed for Bitcoin transaction fees to become small enough to enable micro-transactions, and Ayre believes the Bitcoin Cash blockchain will become the one chain that powers the world, a view shared by the Government of Antigua & Barbuda.


CONTACT: Media Contact: Ed Pownall,

Anti-ageing Cosmeceuticals Market 2017-2027

Antiwrinkle, Antistretch Mark, UV Absorbers, Hair, Topical, Invasive, Acne Therapy, Liposuction, Breast Augmentation, Hair Growth, Eyelid Surgery, Botox, Anti-pigmentation, Abdominoplasty, Other Services

The anti-ageing cosmeceuticals market was worth $11.9bn in 2016. This market is expected to grow at a CAGR of 8.2% from 2017-2027. In 2016, the hair segment dominated the anti-ageing cosmeceuticals market at an estimated value of $3.6bn and held 30% share of this market.

(Logo: )

How this report will benefit you:

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 191-page report you will receive 87 tables and 92 figures – all unavailable elsewhere.

The 191-page report provides clear detailed insight into the anti-ageing cosmeceuticals market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope:

• Anti-ageing cosmeceuticals market forecasts from 2017-2027

• This report also breaks down the revenue forecast for the global Anti-ageing cosmeceuticals market by product:
• Anti-wrinkle
• Anti-stretch mark
• UV absorbers
• Hair
• Others Products

The forecast of each submarket is further broken down by region (North AmericaSouth AmericaEuropeAsia-Pacific, RoW)

• This report breaks down the revenue forecast for the global Anti-ageing cosmeceuticals market by delivery method:
• Topical
• Invasive

The forecast of each submarket is further broken down by region (North AmericaSouth AmericaEuropeAsia-Pacific, RoW)

• This report breaks down the revenue forecast for the global Anti-ageing cosmeceuticals market by services:
• Acne Therapy
• Liposuction
• Breast Augmentation
• Hair Growth
• Eyelid Surgery
• Botox
• Anti-pigmentation
• Abdominoplasty
• Other Services

The forecast of each submarket is further broken down by region (North AmericaSouth AmericaEuropeAsia-Pacific, RoW)

• This report provides individual revenue forecasts to 2027 for these regional and national markets:
• North America: the US, CanadaMexico
• South America: Brazil, ArgentinaParaguayBolivia and Rest of South America
• Europe: the UK, GermanyFranceSpainItalyRussia and Rest of Europe
• Asia-Pacific: China, IndiaJapanAustraliaThailand and Rest of Asia-Pacific
• Rest of the World: Middle East, South Africa, Other Countries

• Our study discusses the drivers and restraints that affect the global Anti-ageing cosmeceuticals market. Our study also discusses Porters Five Forces analysis that influence the anti-ageing cosmeceuticals market

• Our study discusses selected leading companies that are the major players in the Anti-ageing cosmeceuticals market.
• Allergan PLC
• Avon Products Inc.
• Beiersdorf AG
• Chanel International B.V.
• Christian Dior SE
• Johnson & Johnson
• Revlon Inc.
• Unilever PLC

Visiongain’s study is intended for anyone requiring commercial analyses for the anti-ageing cosmeceuticals market. You find data, trends and predictions.

Buy our report today Anti-Ageing Cosmeceuticals Market 2017-2027: Anti-wrinkle, Anti-stretch Mark, UV Absorbers, Hair, Topical, Invasive, Acne Therapy, Liposuction, Breast Augmentation, Hair Growth, Eyelid Surgery, Botox, Anti-pigmentation, Abdominoplasty, Other Services.

To request a report overview of this report please email Sara Peerun at or call Tel: +44-(0)-20-7336-6100

Or click on

List of Companies and Organizations Mentioned in the Report:

AIVITA Biomedical

Allergan PLC

Avon Products Inc.

Beiersdorf AG

Boston University School of Public Health

Chanel International B.V.

Christian Dior SE

Elizabeth Arden, Inc

Federal Food, Drug, and Cosmetic Act (FD&C Act)

Food and Drug Administration (FDA)

Johnson & Johnson

Kao Corporation

L’Oreal S.A.


Nu Skin


Procter & Gamble

Revlon Consumer Products Corporation

Revlon, Inc.


The Body Shop International PLC

The Estee Lauder Companies Inc.

Unilever PLC

World Economic Forum

To see a report overview please email Sara Peerun on

SOURCE Visiongain Ltd

How Technology is Fueling the Next Gold Rush

Prospectors have mined 20 million ounces of gold from the Yukon’s famous Klondike since the Gold Rush. But they haven’t been able to find the original source-the multi-billion-dollar bedrock until now. Miners included are Royal Gold, Inc. (NASDAQ: RGLD), Gold Fields Limited (NYSE: GFI), Silver Wheaton Corp. (NYSE: SLW), AngloGold Ashanti Limited (NYSE: AU), IAMGOLD Corporation (NYSE: IAG).

A famous geologist armed with the latest in drone tech and robo-drills is certain he’s just found it. This is the Mother Lode of Klondike gold that countless prospectors have been trying to get at for over a century. It makes the 20 million ounces that have been collected on the surface of the seem like gold dust, a mere flash in the pan. This is no longer a story of men with pick axes trying in vain to find the mega source that’s it’s all come from.

Now it’s a story of an amazing technology that’s enraptured everyone on the Discovery Channel, a Canadian billionaire whose touch turns everything to gold, and a legendary geologist of gold-discovery fame.

The famous geologist is Peter Tallman. The company is Klondike Gold (KG.VKDKGF), and their latest gold discoveries are the stuff of legend.

Not only are they sitting on massive acreage in one of the Gold Rush’s most pre-eminent venues, but they are also positioned in an area that has geology similar to the California Motherlode Belt, where 220 million ounces was discovered.

And the timing is urgent.

What Tallman has already discovered could be enough to make Klondike Gold a prime takeover target.

Here are 5 reasons to look at Klondike Gold (KG.V; KDKGF) right now:

#1 The Gold Discovery of the Century

Tallman believes he’s sitting on one of the sources of the historic Klondike gold fields, and he’s got plenty to prove it.

He’s tested the gold-bearing structure for 2 kilometers, and the gold is there, a source which he believes runs for 8 kilometers. He’s also identified three other gold-bearing structures, each 8 kilometers long.

What does that mean, exactly? It means they’ve got 30 kilometers of gold-bearing structure to test further.

By the end of last year, Klondike’s best drill holes showed 5 g/t over 14 meters and 76 g/t over 3 meters, keeping in mind that the industry average is 1.18 g/t.

These are phenomenal results, and Tallman is far from finished.

Right now, Klondike has three primary targets in its namesake Gold Rush venue:

  • Lone Star is a 70-hole drill program, with results so far showing 2.4 g/t
  • Gold Run is following up on visible gold bedrock samples from last year, with a 10-hole drill program
  • Quartz Creek is continuing exploration, with 2,000 soil samples

Tallman is looking at Lone Star directly above Bonanza Creek-one of the most prolific creeks in the Klondike. Last year alone, they drilled 14 holes here, and all of them hit disseminated gold mineralization. This is unusual even in the Klondike Gold Rush territory.

The ultimate target here is a multi-million-ounce play.

#2 Crazy Cheap Exploration, 100% Ownership & Takeover Potential

All told, with Klondike Gold (KG.VKDKGF) we’re looking at 2,780 contiguous claims covering 524 square kilometers, and this is where it gets really good: 100% ownership, which means 100% of the score on these incredible finds.

The numbers look even better when you consider that they’re paying only $75 per meter for each drill hole.

That makes this the cheapest drill program in the entire Yukon, and one of the cheapest in Canada.

The Klondike is full of gold – it is known for its gold. It is all sitting at the surface so an average drill completed a hole each day.

The brilliant infrastructure helps, as well. Their project is just 20 kilometers south of Dawson. Their compound is only 20 minutes from the drilling area. They can even order a pizza from the town (of Dawson) for delivery at the drill.

That’s why four out of five of the biggest miners in the world are gathered in the Yukon. Of the $1 billion invested in this region so far, 90% of it has been in gold.

The supermajors are all over the Yukon, and Barrick gold was the fourth to hit up this Gold Rush territory in the last 12 months.

And the list of Yukon deals goes on.

What makes this story even better is that even if we don’t get to the Motherlode of the Gold Rush today, the discovery of any mineable deposit would send share prices soaring.

#3 The Motherlode of Technology

Why hasn’t the Klondike Motherlode of gold been found after 40 long years of searching? That’s easy: technology.

It all started in 1896, when George Washington Carmack and two Indian friends found a large gold nugget when they were fishing in what is the Yukon’s Bonanza Creek- Klondike Gold (KG.VKDKGF) primary target area. This gold nugget launched a massive gold rush, but the 20 million ounces scooped up wasn’t ‘mined’-it was placer gold, recovered at the surface.

The men that gathered here en masse to get rich, were armed only with pick axes. They couldn’t get to the hard rock source of the gold, and they wouldn’t have known where, or how, to look. Tallman does and he’s covering every square inch of ground, and underground, here, with a systematic approach and the most advanced technology.

That includes drones, portable ground imaging, robo-drills, Field X-rays and 3D mapping.

What came after the pick axes was invasive heavy equipment, digging huge trenches-all coming up empty-handed.

Modern tech is fast, revealing the age-old secrets of this difficult terrain.

Advanced drones fly out over the entire territory, collecting key geological data. Once the sweet spots are determined by the drone flyovers, it’s time to see what’s under the soil. This advanced geophysical survey technology allows for the 3D imaging of slices of the subsurface in great detail by running electrical currents into the ground. This tells operators whether to drill or not to drill.

If the geophysical survey shows the gold signature, the robo-drill is ushered in. It’s fully mobile on pretty much any terrain-it doesn’t even need a road. The robo-drill brings up samples that are then analyzed on site with advanced, mobile x-ray technology.

The drone images, the geophysical survey results and the analysis are all channeled directly to Tallman’s computer at Klondike’s compound.

And gold eventually gives itself up to modern technology.

#4 Reborn into a Legend

Klondike Gold (KG.VKDKGF) wasn’t always the stuff of legend.

At least not until Canadian billionaire and mining finance legend Frank Giustra decided, in 2014, that it was time to revive the Klondike Gold Rush. So he brought in a famous geologist to make waves where waters had grown stagnant.

Giustra, who owns 22% of the company, turned to Tallman, a technology genius with 35 years of experience and a string of phenomenal discoveries behind him.

Giustra tasked Tallman with finding out where the money went under Klondike’s previous mismanagement; and finding out whether its vast properties are profitable.

In record time, Tallman had paid off the company’s debt, cleaned house, and made a beeline for the geology-finding visible gold in bedrock right away.

The verdict: Not only was Klondike’s property ‘good’, it was exceptional: It’s sitting on channel gravels that have given up 20 million ounces of placer gold (worth $25 billion USD today).

Fast forward to less than three years later – Tallman is convinced that a fault system he’s identified along with a series of fractures extending from Bonanza Creek down to Eldorado Creek were the source bedrock of all that Gold Rush gold.

Giustra didn’t pick Tallman at random. The mining finance legend is known not only for being in the right place, at the right time, but for putting together dream teams to make things happen fast.

And the ‘things’ he makes happen always include a great deal of shareholder value, tens of billions of dollars:

He built up giant Goldcorp) in 2000 and today it trades at a market cap of nearly $11 billion, and is one of the largest gold-mining companies in the world. He was also behind Silver Wheaton, which is now Wheaton Precious Metals Corp., the biggest silver and gold streaming company in the world.

Giustra’s 20-oscar-winning entertainment behemoth, Lion’s Gate, also took in $2.4 billion in revenue in 2015. And these are just a few of his multi-billion-dollar companies.

But back to Tallman, who owns 3.6% of outstanding shares in Klondike himself.

Tallman, the CEO and President of Klondike Gold Corp. since 2014, is not just a genius geologist, he’s a master businessman – a rare combination in the industry. So rare, in fact, that legendary businessman Murray ‘The Pez’ Pezim hired him to oversee around 80 companies in his portfolio. ‘The Pez’ put two of Canada’s premier gold deposits (Hemlo and Eskay Creek) on the world map.

In the world of geology and gold, Tallman is a larger than life figure. And Giustra’s counting on him to continue his record of superstar discoveries with Klondike.

He’s already discovered three deposits, two of which have been mined.

But he also put his business acumen to work-with a passion. By late 2014, he had optioned one of the company’s properties off to The Discovery Channel’s ‘Gold Rush’ program, earning the Klondike C$750,000 in return and also garnering it massive exposure.

Under Tallman, the company has no debt, a tightly-held share structure and money in the bank. It’s reborn, flush, and ready to break out with the next major Gold Rush story.

#5 New Drilling Results SOON

Based on Tallman’s geology, and the rapid flow of news for Klondike Gold (KG.V; KDKGF), we expect significant momentum on shares in the coming weeks and months.

The 2.4 g/t results from 2 holes at Lone Star on 11 July, was just the beginning of what promises to be a massive barrage of great news.

While the Lone Star project focuses full throttle on exploration, 30 holes have already been drilled this year alone, and the results will start coming in any day.

In fact, we expect major news from Klondike every week or two from now until November.

And they’re fully funded to drill 80 holes, so that’s 50 more to go and they’ll finish drilling in late October.

A recent private placement also gave them more money to spend on drilling.

The drilling results themselves are bound to attract the majors who have already shown a hearty appetite for swooping in on the juniors making waves in the Yukon Gold Rush territory.

The Klondike is the largest remaining unsourced chemical anomaly on the planet, and Tallman has parachuted in with a singular objective-to find the original source of all that gold in the bedrock.

And he’s watching what’s happening around him like a hawk. Klondike’s neighbor, Kaminak, was already bought for half a billion by giant Goldcorp. Another neighbor, Underworld, was bought by Kinross for $140 million. Both of their mining roads pass right through the middle of Klondike’s.

Bottom Line?

  • Superstar team, with geology genius, advanced technology and billionaire backing
  • Potential bulk gold tonnage identified
  • Possible motherlode source of historical Gold Rush gold
  • Fully financed and funded to drill another 50 holes
  • High-speed news flow, with results expected every week from now until year-end
  • Fantastic shareholder structure, with management and insiders holding over half of the company and believing in it
  • If Klondike’s exceptional results prove continuity, we’ll be looking at a prime takeover target and a potentially significant shift in share prices heading into the third quarter of this year and the first quarter of 2018.

Honorable Mentions

Royal Gold (NASDAQ: RGLD): Royal Gold is engaged in the acquisition, and management of precious metals royalties and streams. Royal does not only focus on gold, it also has royalty claims on silver, zinc, copper and lead in over 20 countries. As commodity prices rise, we expect that more of its unexplored properties will come into production.

Gold Fields Limited (NYSE: GFI): South African Gold Fields produced 2.15 million oz. of gold equivalent in 2016, slightly lower than its 2015. It owns and operates mines in South AfricaGhanaAustralia and Peru. Its growth efforts are focused mainly in the regions where it already has a footprint and are mainly driven through brownfields exploration. Unlike its smaller counterparts, Gold Fields yields a modest dividend.

Silver Wheaton (NYSE: SLW): Silver Wheaton Corp. is a pure play silver mining company, and the largest in the business of silver streaming. It produces over 26 million ounces and sells over 29 million ounces of silver mined by other companies such as Barrick and Goldcorp as a by-product of their main operations. Wheaton pays a healthy dividend and has actually profited from the most recent downturn in commodities.

AngloGold Limited (NYSE: AU): AngloGold is a major gold company, mining some 7 million ounces a year, with estimated reserves of 126 million ounces. The company operates in 11 countries. The company’s stock fell steep over the last few months, but a rebound could be on the horizon as gold prices are rising again.

IAMGOLD (NYSE: IAG): IAMGOLD is a fast growing mid-tier gold miner with the ambition to become a major gold miner. The company produced some 214,000 ounces in Q1 2017 from its operations in South America and Africa. In June, this promising miner closed a deal with Japanese commodity giant Sumitomo to develop an Ontario gold project. The company saw its stock price fall earlier this year, but is poised for gains as gold is rallying

By. James Burgess

Legal Disclaimer/Disclosure from This piece is an advertorial and has been paid for. This document is not and should not be construed as an offer to sell or the solicitation of an offer to purchase or subscribe for any investment. No information in this Report should be construed as individualized investment advice. A licensed financial advisor should be consulted prior to making any investment decision. We make no guarantee, representation or warranty and accept no responsibility or liability as to its accuracy or completeness. Expressions of opinion are those of only and are subject to change without notice. assumes no warranty, liability or guarantee for the current relevance, correctness or completeness of any information provided within this Report and will not be held liable for the consequence of reliance upon any opinion or statement contained herein or any omission. Furthermore, we assume no liability for any direct or indirect loss or damage or, in particular, for lost profit, which you may incur as a result of the use and existence of the information, provided within this Report. All content contained herein is subject to the terms and conditions set forth in the original article posted on and subject to the terms and conditions therein.

DISCLAIMER: is Source of all content listed above. FN Media Group, LLC (FNM), is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with or any company mentioned herein. The commentary, views and opinions expressed in this release by are solely those of and are not shared by and do not reflect in any manner the views or opinions of FNM. FNM is not liable for any investment decisions by its readers or subscribers. FNM and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM was not compensated by any public company mentioned herein to disseminate this press release.


This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

Contact Information:
Media Contact e-mail:
U.S. Phone: +1(954)345-0611



Johnson Controls announces accelerated leadership succession

Johnson Controls International plc (NYSE: JCI) today announced effective Sept. 1, 2017George Oliver, currently president and chief operating officer, will assume the role of Chairman and CEO.  This action accelerates the move of Mr. Oliver to his new position six months earlier than previously announced. The acceleration was unanimously approved by the company’s board of directors. Mr. Molinaroli, currently chairman and CEO, will leave the company and the board effective Sept. 1, 2017.

In addition, the company announced that Jürgen Tinggren, chair of the audit committee and a member of the executive committee, has been appointed lead independent director of the Johnson Controls board of directors, effectively immediately.  Separately, the company announced that Jeffrey A. Joerres has stepped down from the board of directors.

Mr. Tinggren said, “Given the progress made on the merger integration as we approach the one-year anniversary and upcoming start of a new fiscal year, this is an opportune and appropriate time to implement this planned leadership succession. The board has been impressed by George’s leadership and oversight of the integration, and we believe accelerating the transition provides clarity and continuity as we move into the next phase and continue to deliver the benefits of the transaction and enhance long-term shareholder value.

Tinggren added, “On behalf of the entire board, I want to thank Alex Molinaroli for his many years of outstanding service and leadership.  He has led Johnson Controls through a period of unparalleled strategic transformation and helped position the combined company for success as the leader in buildings and energy storage solutions.”

Mr. Oliver said, “I am honored by the trust the board has placed in me and look forward to building on the progress we have made in combining the companies. Since completing the Tyco merger, we have been executing a robust integration plan to maximize the skill sets and capabilities of the combined company, develop solutions to better meet our customers’ needs and realize approximately $1 billionof cost savings.  As CEO, I will continue working with the board and our employees around the world to deliver on the Johnson Controls promise to make the world a more productive, secure and sustainable place.  I would like to thank Alex for his direction and partnership, both before and during this critical year of change.”

Mr. Molinaroli said, “It’s been an honor to lead Johnson Controls since 2013, and I want to thank all of our employees for their continued trust, commitment and incredible contributions.  The company has a great strategic foundation and is well-positioned for growth as a market leader in buildings and energy solutions.  I’m confident as I’ve worked with George over the past year that he and his management team are well-positioned to propel the company forward.”

Mr. Joerres stated, “It has been an honor to have served on the Johnson Controls board for the last 16 years.  I thank Alex for his dedicated service and am confident that the company will be well-served under George’s capable leadership.”

About Johnson Controls:

Johnson Controls is a global diversified technology and multi industrial leader serving a wide range of customers in more than 150 countries. Our 120,000 employees create intelligent buildings, efficient energy solutions, integrated infrastructure and next generation transportation systems that work seamlessly together to deliver on the promise of smart cities and communities. Our commitment to sustainability dates back to our roots in 1885, with the invention of the first electric room thermostat. We are committed to helping our customers win and creating greater value for all of our stakeholders through strategic focus on our buildings and energy growth platforms. For additional information, please visit or follow us @johnsoncontrols on Twitter.

Johnson Controls International plc Cautionary Statement Regarding Forward-Looking Statements

Johnson Controls International plc has made statements in this communication that are forward-looking and therefore are subject to risks and uncertainties. All statements in this document other than statements of historical fact are, or could be, “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. In this communication, statements regarding Johnson Controls’ future financial position, sales, costs, earnings, cash flows, other measures of results of operations, synergies and integration opportunities, capital expenditures and debt levels are forward-looking statements. Words such as “may,” “will,” “expect,” “intend,” “estimate,” “anticipate,” “believe,” “should,” “forecast,” “project” or “plan” and terms of similar meaning are also generally intended to identify forward-looking statements. However, the absence of these words does not mean that a statement is not forward-looking. Johnson Controls cautions that these statements are subject to numerous important risks, uncertainties, assumptions and other factors, some of which are beyond Johnson Controls’ control, that could cause Johnson Controls’ actual results to differ materially from those expressed or implied by such forward-looking statements, including, among others, risks related to: any delay or inability of Johnson Controls to realize the expected benefits and synergies of recent portfolio transactions such as the merger with Tyco and the spin-off of Adient, changes in tax laws, regulations, rates, policies or interpretations, the loss of key senior management, the tax treatment of recent portfolio transactions, significant transaction costs and/or unknown liabilities associated with such transactions, the outcome of actual or potential litigation relating to such transactions, the risk that disruptions from recent transactions will harm Johnson Controls’ business, the strength of the U.S. or other economies, automotive vehicle production levels, mix and schedules, energy and commodity prices, the availability of raw materials and component products, currency exchange rates, and cancellation of or changes to commercial arrangements. A detailed discussion of risks related to Johnson Controls’ business is included in the section entitled “Risk Factors” in Johnson Controls’ Annual Report on Form 10-K for the 2016 year filed with the SEC on November 23, 2016, and in the quarterly reports on Form 10-Q filed with the SEC after such date, and available at and under the “Investors” tab. Shareholders, potential investors and others should consider these factors in evaluating the forward-looking statements and should not place undue reliance on such statements. The forward-looking statements included in this communication are made only as of the date of this document, unless otherwise specified, and, except as required by law, Johnson Controls assumes no obligation, and disclaims any obligation, to update such statements to reflect events or circumstances occurring after the date of this communication.



Antonella Franzen

(609) 720-4665

Ryan Edelman

(609) 720-4545


Fraser Engerman

(414) 524-2733


SOURCE Johnson Controls


Perrigo Announces Final FDA Approval And Settlement For The Store Brand OTC Equivalent Of Nexium® 24HR Capsules

Perrigo Company plc (NYSE; TASE: PRGO) today announced that it has received final approval from the U.S. Food & Drug Administration for the store brand OTC equivalent of Nexium® 24HR (esomeprazole magnesium) capsules. The company also announced that it has reached a settlement of patent litigation with AstraZeneca allowing for the store brand OTC equivalent of Nexium® 24HR (esomeprazole magnesium) capsules to launch in late September 2017. This product will be packaged and marketed as store brand or retailer ‘own label’ brand and will provide consumers with a high-quality, value alternative to Nexium® 24HR capsules.

Nexium® 24HR (esomeprazole magnesium) capsules are indicated to treat frequent heartburn (occurs 2 or more days a week).  Approximate annual retail sales for the last 12 months were in excess of $300 million.

Perrigo Executive Vice President and President, Consumer Healthcare Americas Jeff Needham stated, “This final approval and upcoming launch demonstrates the tremendous capabilities of our leading store brand OTC platform. We are eager to finalize launch plans with our retail and wholesale partners to bring this major new product to consumers. Important product launches like the store brand equivalent of Nexium® 24HR capsules are what drive the Perrigo advantage by providing our customers, consumers and families with high quality, value alternatives in important treatment categories.”

About Perrigo 

Perrigo Company plc, a leading global healthcare company, delivers value to its customers and consumers by providing Quality Affordable Healthcare Products®. Founded in 1887 as a packager of home remedies, Perrigo has built a unique business model that is best described as the convergence of a fast-moving consumer goods company, a high-quality pharmaceutical manufacturing organization and a world-class supply chain network. Perrigo is the world’s largest manufacturer of over-the-counter (“OTC”) healthcare products and supplier of infant formulas for the store brand market. The Company also is a leading provider of branded OTC products throughout Europe and the U.S., as well as a leading producer of “extended topical” prescription drugs. Perrigo, headquartered in Ireland, sells its products primarily in North America and Europe, as well as in other markets, including Australia, Israel and China. Visit Perrigo online at (

Forward-Looking Statements

Certain statements in this press release are “forward-looking statements.” These statements relate to future events or the Company’s future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “potential” or the negative of those terms or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company’s control, including: the timing, amount and cost of any share repurchases; future impairment charges; the success of management transition; customer acceptance of new products; competition from other industry participants, some of whom have greater marketing resources or larger market shares in certain product categories than the Company does; pricing pressures from customers and consumers; potential third-party claims and litigation, including litigation relating to the Company’s restatement of previously-filed financial information; potential impacts of ongoing or future government investigations and regulatory initiatives; general economic conditions; fluctuations in currency exchange rates and interest rates; the consummation of announced acquisitions or dispositions, and the Company’s ability to realize the desired benefits thereof; the Company’s ability to achieve its guidance; and the Company’s ability to execute and achieve the desired benefits of announced cost-reduction efforts and other initiatives.  In addition, the Company may identify and be unable to remediate one or more material weaknesses in its internal control over financial reporting. Furthermore, the Company and/or its subsidiaries may incur additional tax liabilities in respect of 2016 and prior years as a result of any restatement or may be found to have breached certain provisions of Irish company legislation in respect of prior financial statements and if so may incur additional expenses and penalties. These and other important factors, including those discussed under “Risk Factors” in the Company’s Form 10-K for the year ended December 31, 2016, as well as the Company’s subsequent filings with the United States Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Perrigo Company plc

CONTACT: Perrigo Contacts: Bradley Joseph, Vice President, Global Investor Relations & Corporate Communications, (269) 686-3373, E-mail:


Perrigo Company plc (NYSE; TASE: PRGO) today announced that it has received final approval from the U.S. Food & Drug Administration for the store brand OTC equivalent of Nexium® 24HR (esomeprazole magnesium) capsules. The company also announced that it has reached a settlement of patent litigation with AstraZeneca allowing for the store brand OTC equivalent of Nexium® 24HR (esomeprazole magnesium) capsules to launch in late September 2017. This product will be packaged and marketed as store brand or retailer ‘own label’ brand and will provide consumers with a high-quality, value alternative to Nexium® 24HR capsules.

Nexium® 24HR (esomeprazole magnesium) capsules are indicated to treat frequent heartburn (occurs 2 or more days a week).  Approximate annual retail sales for the last 12 months were in excess of $300 million.

Perrigo Executive Vice President and President, Consumer Healthcare Americas Jeff Needham stated, “This final approval and upcoming launch demonstrates the tremendous capabilities of our leading store brand OTC platform. We are eager to finalize launch plans with our retail and wholesale partners to bring this major new product to consumers. Important product launches like the store brand equivalent of Nexium® 24HR capsules are what drive the Perrigo advantage by providing our customers, consumers and families with high quality, value alternatives in important treatment categories.”

About Perrigo 

Perrigo Company plc, a leading global healthcare company, delivers value to its customers and consumers by providing Quality Affordable Healthcare Products®. Founded in 1887 as a packager of home remedies, Perrigo has built a unique business model that is best described as the convergence of a fast-moving consumer goods company, a high-quality pharmaceutical manufacturing organization and a world-class supply chain network. Perrigo is the world’s largest manufacturer of over-the-counter (“OTC”) healthcare products and supplier of infant formulas for the store brand market. The Company also is a leading provider of branded OTC products throughout Europe and the U.S., as well as a leading producer of “extended topical” prescription drugs. Perrigo, headquartered in Ireland, sells its products primarily in North America and Europe, as well as in other markets, including Australia, Israel and China. Visit Perrigo online at (

Forward-Looking Statements

Certain statements in this press release are “forward-looking statements.” These statements relate to future events or the Company’s future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “potential” or the negative of those terms or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company’s control, including: the timing, amount and cost of any share repurchases; future impairment charges; the success of management transition; customer acceptance of new products; competition from other industry participants, some of whom have greater marketing resources or larger market shares in certain product categories than the Company does; pricing pressures from customers and consumers; potential third-party claims and litigation, including litigation relating to the Company’s restatement of previously-filed financial information; potential impacts of ongoing or future government investigations and regulatory initiatives; general economic conditions; fluctuations in currency exchange rates and interest rates; the consummation of announced acquisitions or dispositions, and the Company’s ability to realize the desired benefits thereof; the Company’s ability to achieve its guidance; and the Company’s ability to execute and achieve the desired benefits of announced cost-reduction efforts and other initiatives.  In addition, the Company may identify and be unable to remediate one or more material weaknesses in its internal control over financial reporting. Furthermore, the Company and/or its subsidiaries may incur additional tax liabilities in respect of 2016 and prior years as a result of any restatement or may be found to have breached certain provisions of Irish company legislation in respect of prior financial statements and if so may incur additional expenses and penalties. These and other important factors, including those discussed under “Risk Factors” in the Company’s Form 10-K for the year ended December 31, 2016, as well as the Company’s subsequent filings with the United States Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Perrigo Company plc

CONTACT: Perrigo Contacts: Bradley Joseph, Vice President, Global Investor Relations & Corporate Communications, (269) 686-3373, E-mail:


Amgen To Present New Data From The Repatha® (Evolocumab) Cardiovascular Outcomes Study At ESC Congress 2017

Amgen (NASDAQ:AMGN) today announced that new data from the Repatha® (evolocumab) clinical trial program, including three late-breaking scientific sessions, will be presented at the European Society of Cardiology (ESC) Congress 2017 in Barcelona, SpainAug. 26-30, 2017. New data includes additional efficacy and safety analyses from the Repatha cardiovascular outcomes trial (FOURIER) and the Repatha coronary intravascular ultrasound imaging trial (GLAGOV).

“Data from the Repatha clinical trial program continue to reinforce the value of this innovative medicine for patients at risk of a heart attack or stroke,” said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. “We look forward to sharing the breadth of data demonstrating Repatha’s ability to lower LDL cholesterol and reduce cardiovascular events, including the effect of Repatha in patients with a history of stroke.”

Data from the Repatha cardiovascular outcomes trial assessing the effect of Repatha on cardiovascular outcomes in patients with a history of stroke will be presented in a late-breaking science session (Clinical Trial Update 2) along with a new analysis from the GLAGOV  trial. A second analysis of the Repatha cardiovascular outcomes trial, assessing the efficacy and safety of achieving very low low-density lipoprotein cholesterol (LDL-C) levels with Repatha, will be presented in the late-breaking Clinical Trial Update 1 session.

Amgen-sponsored abstracts at ESC Congress 2017 include:



Late-Breaking Science Sessions

  • Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial
    Clinical Trial Update 1, Monday, Aug. 28, 2:30 – 2:45 p.m. CEST
  • Effect of the PCSK9 Inhibitor, Evolocumab, on the Composition of Coronary Atherosclerosis: Insights on the GLAGOV Trial
    Clinical Trial Update 2, Tuesday, Aug. 29, 4:45 – 5 p.m. CEST
  • Further Cardiovascular OUtcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (Focus on Cerebrovascular Disease)
    Clinical Trial Update 2, Tuesday, Aug. 29, 5 – 5:15 p.m. CEST

Poster Sessions

  • Efficacy and Safety of Evolocumab Compared With Continued Lipoprotein Apheresis: Results of a Randomised, Controlled, Open-Label Study
    Late-Breaking Science Posters, Sunday, Aug. 278:30 a.m. – 6 p.m. CEST
    Moderated Session, 3:35 – 4:25 p.m. CEST
  • Evolocumab Treatment in Paediatric Patients With Homozygous Familial Hypercholesterolaemia: the Trial Assessing Long-Term Use of PCSK9 Inhibition in Subjects With Genetic LDL Disorders (TAUSSIG)
    Rapid Fire Session, Lipid Lowering Therapy in Primary Cardiovascular Prevention, Monday, Aug. 28, 12:12 – 12:21 p.m. CEST
  • Evolocumab Lowers Plasma Lp(a) Concentration by Two Kinetic Modes of Action: From the FLOREY Study
    Lipid Metabolism, Monday, Aug. 288:30 a.m. – 12:30 p.m. CEST
    Moderated Session: 10:05 – 10:55 a.m. CEST
  • Is Lipoprotein(a) Metabolism Linked to the Transport and Catabolic Rates of Apolipoprotein B-100 Containing Lipoproteins?
    Lipid Metabolism, Monday, Aug. 288:30 a.m. – 12:30 p.m. CEST
    Moderated Session: 10:05 – 10:55 a.m. CEST

Observational Research

  • Changes in Lipid-lowering Therapy Prescription Patterns Following a Second Cardiovascular Disease Event
    Lipid-lowering Therapy: Old Faces and New Issues, Saturday, Aug. 2611 a.m. – 4 p.m. CEST
    Moderated Session, 12:35 – 1:25 p.m. CEST
  • Evaluation of Statin Users, People With Hypercholesterolemia, and Cardiovascular Disease Patients in the Japan Medical Data Center Claims Database
    Poster Session 1: Treatment of Dyslipidaemia, Saturday, Aug. 2611 a.m. – 4 p.m. CEST
  • Statin Use Among HIV-Infected Adults by Cardiovascular Disease Risk Status
    Lipid-lowering Therapy: Old Faces and New Issues, Saturday, Aug. 2611 a.m. – 4 p.m. CEST
    Moderated Session, 12:35 – 1:25 p.m. CEST
  • Adherence to Intensive Medical Management in the Year Following Hospitalization for Myocardial Infarction
    Poster Session 5: Prevention – Epidemiology, Monday, Aug. 28, 2 – 6 p.m. CEST
  • Characterizing Familial Hypercholesterolemia in an Electronic Health Record (EHR) Database
    Poster Session 6: Lipids, Obesity and Metabolic Syndrome, Tuesday, Aug. 298:30 a.m. – 12:30 p.m. CEST

Health Economics

  • Lack of Low-Density Lipoprotein Cholesterol (LDL-C) Goal Attainment Among High-Risk Patients Using High or Moderate Intensity Statin Therapy in Germany
    Best Posters 3: Best Posters in New Targets in Cardiovascular Drug Assessment, Sunday, Aug. 27, 2 – 6 p.m. CEST
    Discussant Review, 3:35 – 4:25 p.m. CEST

Corlanor® (ivabradine)

Observational Research

  • Increased Heart Rate is Independently Associated With Worse Survival in Pediatric Patients with Dilated Cardiomyopathy: a Multicenter Study From the Pediatric Cardiomyopathy Registry
    Contemporary Management of Risk Factors in Congenital Heart Disease, Sunday, Aug. 278:57 – 9:06 a.m. CEST

Repatha Cardiovascular Outcomes (FOURIER) Study Design
The 27,564-patient Repatha cardiovascular outcomes study, FOURIER (Further Cardiovascular OUtcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk), was a multinational Phase 3 randomized, double-blind, placebo-controlled trial, designed to evaluate whether treatment with Repatha in combination with statin therapy compared to placebo plus statin therapy reduces cardiovascular events. The primary endpoint was time to cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization. The key secondary endpoint was the time to cardiovascular death, myocardial infarction or stroke.

Eligible patients with high cholesterol (LDL-C ≥70 mg/dL or non-high-density lipoprotein cholesterol [non-HDL-C] ≥100 mg/dL) and clinically evident atherosclerotic cardiovascular disease at more than 1,200 study locations around the world were randomized to receive Repatha subcutaneous 140 mg every two weeks or 420 mg monthly plus optimized statin dose; or placebo subcutaneous every two weeks or monthly plus optimized statin dose. Optimized statin therapy was defined as at least atorvastatin 20 mg or equivalent daily with a recommendation for at least atorvastatin 40 mg or equivalent daily where approved. The study was event driven and continued until 1,630 patients experienced a key secondary endpoint.

GLAGOV Study Design
GLAGOV (GLobal Assessment of Plaque ReGression with a PCSK9 AntibOdy as Measured by IntraVascular Ultrasound) is a Phase 3, multicenter, double-blind, randomized, placebo-controlled trial designed to evaluate the effect of Repatha on the change in burden of coronary artery disease (CAD) in 968 patients undergoing clinically indicated coronary angiogram and on optimized background statin therapy.

Patients were required to have been treated with a stable statin dose for at least four weeks and to have a LDL-C ≥80 mg/dL or between 60 and 80 mg/dL with one major cardiovascular risk factor (defined as non-coronary atherosclerotic vascular disease, myocardial infarction or hospitalization for unstable angina in the preceding two years or type 2 diabetes mellitus) or three minor cardiovascular risk factors (defined as current cigarette smoking, hypertension, low levels of HDL cholesterol, family history of premature coronary heart disease, high sensitivity C-reactive protein (hs-CRP) ≥2 mg/L or age ≥50 years in men and 55 years in women).

Patients were randomized 1:1 into two treatment groups to either receive monthly Repatha 420 mg or placebo subcutaneous injections. Optimized statin therapy was defined as at least atorvastatin 20 mg daily or equivalent, titrated to achieve LDL-C reduction per regional guidelines. Highly effective statin therapy (equivalent to atorvastatin 40 mg daily or higher) was recommended for all patients. Those patients with LDL-C >100 mg/dL not taking highly effective statin therapy, required investigators’ attestation as to why such doses were not appropriate. The primary endpoint was change in percent atheroma volume (PAV) from baseline to week 78 compared to placebo, as determined by intravascular ultrasound (IVUS). IVUS is a high-resolution imaging tool that allows for the quantification of coronary atheroma in the coronary arteries.

Secondary endpoints included PAV regression (any reduction from baseline); change in total atheroma volume (TAV) from baseline to week 78; and regression (any reduction from baseline) in TAV.

About Repatha® (evolocumab)
Repatha® (evolocumab) is a human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). Repatha binds to PCSK9 and inhibits circulating PCSK9 from binding to the low-density lipoprotein (LDL) receptor (LDLR), preventing PCSK9-mediated LDLR degradation and permitting LDLR to recycle back to the liver cell surface. By inhibiting the binding of PCSK9 to LDLR, Repatha increases the number of LDLRs available to clear LDL from the blood, thereby lowering LDL-C levels.1

Repatha is approved in more than 50 countries, including the U.S., Japan, Canada and in all 28 countries that are members of the European Union. Applications in other countries are pending.

U.S. Repatha Indication
Repatha® is indicated as an adjunct to diet and:

  • Maximally tolerated statin therapy for treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD), who require additional lowering of low-density lipoprotein cholesterol (LDL-C)
  • Other LDL-lowering therapies (e.g., statins, ezetimibe, LDL apheresis) in patients with homozygous familial hypercholesterolemia (HoFH) who require additional lowering of LDL-C

The effect of Repatha® on cardiovascular morbidity and mortality has not been determined.

The safety and effectiveness of Repatha® have not been established in pediatric patients with HoFH who are younger than 13 years old.

The safety and effectiveness of Repatha® have not been established in pediatric patients with primary hyperlipidemia or HeFH.

Important U.S. Safety Information
Contraindication: Repatha® is contraindicated in patients with a history of a serious hypersensitivity reaction to Repatha®.

Allergic reactions: Hypersensitivity reactions (e.g. rash, urticaria) have been reported in patients treated with Repatha®, including some that led to discontinuation of therapy. If signs or symptoms of serious allergic reactions occur, discontinue treatment with Repatha®, treat according to the standard of care, and monitor until signs and symptoms resolve.

Adverse reactions: The most common adverse reactions (>5% of Repatha®-treated patients and more common than placebo) were: nasopharyngitis, upper respiratory tract infection, influenza, back pain, and injection site reactions.

In a 52-week trial, adverse reactions led to discontinuation of treatment in 2.2% of Repatha®-treated patients and 1% of placebo-treated patients. The most common adverse reaction that led to Repatha® treatment discontinuation and occurred at a rate greater than placebo was myalgia (0.3% versus 0% for Repatha® and placebo, respectively).

Adverse reactions from a pool of the 52-week trial and seven 12-week trials: Local injection site reactions occurred in 3.2% and 3.0% of Repatha®-treated and placebo-treated patients, respectively. The most common injection site reactions were erythema, pain, and bruising. The proportions of patients who discontinued treatment due to local injection site reactions in Repatha®-treated patients and placebo-treated patients were 0.1% and 0%, respectively.

Allergic reactions occurred in 5.1% and 4.7% of Repatha®-treated and placebo-treated patients, respectively. The most common allergic reactions were rash (1.0% versus 0.5% for Repatha® and placebo, respectively), eczema (0.4% versus 0.2%), erythema (0.4% versus 0.2%), and urticaria (0.4% versus 0.1%).

Neurocognitive events were reported in less than or equal to 0.2% in Repatha®-treated and placebo-treated patients.

In a pool of placebo- and active-controlled trials, as well as open-label extension studies that followed them, a total of 1,988 patients treated with Repatha® had at least one LDL-C value <25 mg/dL. Changes to background lipid-altering therapy were not made in response to low LDL-C values, and Repatha® dosing was not modified or interrupted on this basis. Although adverse consequences of very low LDL-C were not identified in these trials, the long-term effects of very low levels of LDL-C induced by Repatha® are unknown.

Musculoskeletal adverse reactions were reported in 14.3% of Repatha®-treated patients and 12.8% of placebo-treated patients. The most common adverse reactions that occurred at a rate greater than placebo were back pain (3.2% versus 2.9% for Repatha® and placebo, respectively), arthralgia (2.3% versus 2.2%), and myalgia (2.0% versus 1.8%).

Homozygous Familial Hypercholesterolemia (HoFH): In 49 patients with homozygous familial hypercholesterolemia studied in a 12-week, double-blind, randomized, placebo-controlled trial, 33 patients received 420 mg of Repatha® subcutaneously once monthly. The adverse reactions that occurred in at least 2 (6.1%) Repatha®-treated patients and more frequently than in placebo-treated patients, included upper respiratory tract infection (9.1% versus 6.3%), influenza (9.1% versus 0%), gastroenteritis (6.1% versus 0%), and nasopharyngitis (6.1% versus 0%).

Immunogenicity: Repatha® is a human monoclonal antibody. As with all therapeutic proteins, there is a potential for immunogenicity with Repatha®.

Please contact Amgen Medinfo at 800-77-AMGEN (800-772-6436) or 844-REPATHA (844-737-2842) regarding Repatha® availability or find more information, including full Prescribing Information, at and

Important EU Product Information
In Europe Repatha is approved for use in:

Hypercholesterolemia and mixed dyslipidemia
Repatha is indicated in adults with primary hypercholesterolemia (heterozygous familial and non-familial) or mixed dyslipidemia, as an adjunct to diet:

  • in combination with a statin or statin with other lipid lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin or,
  • alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.

Homozygous familial hypercholesterolemia
Repatha is indicated in adults and adolescents aged 12 years and over with homozygous familial hypercholesterolemia in combination with other lipid-lowering therapies.

The effect of Repatha on cardiovascular morbidity and mortality has not yet been determined.

Primary hypercholesterolemia and mixed dyslipidemia in adults
The recommended dose of Repatha is either 140 mg every two weeks or 420 mg once monthly; both doses are clinically equivalent.

Homozygous familial hypercholesterolemia in adults and adolescents aged 12 years and over
The initial recommended dose is 420 mg once monthly. After 12 weeks of treatment, dose frequency can be up-titrated to 420 mg once every 2 weeks if a clinically meaningful response is not achieved. Patients on apheresis may initiate treatment with 420 mg every two weeks to correspond with their apheresis schedule.

Important Safety Information
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Contraindications: Hypersensitivity to the active substance or to any of the excipients.

Special Warnings and Precautions: Renal impairment: Patients with severe renal impairment (defined as eGFR < 30 mL/min/1.73 m2) have not been studied. Repatha should be used with caution in patients with severe renal impairment. Hepatic impairment: In patients with moderate hepatic impairment, a reduction in total evolocumab exposure was observed that may lead to a reduced effect on LDL‑C reduction. Therefore, close monitoring may be warranted in these patients. Patients with severe hepatic impairment (Child-Pugh C) have not been studied. Repatha should be used with caution in patients with severe hepatic impairment. Dry natural rubber: The needle cover of the glass pre-filled syringe and of the pre-filled pen is made from dry natural rubber (a derivative of latex), which may cause allergic reactions. Sodium content: Repatha contains less than 1 mmol sodium (23 mg) per dose, i.e. it is essentially ‘sodium-free’.

Interactions: No formal drug-drug interaction studies have been conducted for Repatha. No studies on pharmacokinetic and pharmacodynamics interaction between Repatha and lipid-lowering drugs other than statins and ezetimibe have been conducted.

Fertility, Pregnancy and Lactation: There are no or limited amount of data from the use of Repatha in pregnant women. Repatha should not be used during pregnancy unless the clinical condition of the woman requires treatment with evolocumab. It is unknown whether evolocumab is excreted in human milk. A risk to breastfed newborns/infants cannot be excluded. No data on the effect of evolocumab on human fertility are available.  

Undesirable Effects: The following common (> 1/100 to < 1/10) adverse reactions have been reported in pivotal, controlled clinical studies: influenza, nasopharyngitis, upper respiratory tract infection, rash, nausea, back pain, arthralgia, injection site reactions. Please consult the SmPC for a full description of undesirable effects.

Pharmaceutical Precautions: Store in a refrigerator (2 degrees C – 8 degrees C). Do not freeze. Keep the pre-filled syringe or the pre-filled pen in the original carton in order to protect from light. If removed from the refrigerator, Repatha may be stored at room temperature (up to 25 degrees C) in the original carton and must be used within 1 month.

About Corlanor® (ivabradine)
Corlanor® (ivabradine) blocks the hyperpolarization-activated cyclic nucleotide-gated (HCN) channel responsible for the cardiac pacemaker, which regulates heart rate. Corlanor reduces the spontaneous pacemaker activity of the cardiac sinus node by selectively inhibiting the If current (“funny” current) to slow the heart rate with no effect on ventricular repolarization and no effects on myocardial contractility.2 Corlanor was developed by Servier. Through a collaboration with Servier, Amgen has rights to commercialize Corlanor in the U.S.

U.S. Corlanor Indication:
Corlanor® is indicated to reduce the risk of hospitalization for worsening heart failure in patients with stable, symptomatic chronic heart failure with left ventricular ejection fraction < 35%, who are in sinus rhythm with resting heart rate > 70 beats per minute (bpm) and either are on maximally tolerated doses of beta blockers or have a contraindication to beta blocker use.

Important U.S. Safety Information
Contraindications: Corlanor® is contraindicated in patients with acute decompensated heart failure, blood pressure < 90/50 mmHg, sick sinus syndrome, sinoatrial block, 3rd degree atrioventricular (AV) block (unless a functioning demand pacemaker is present), a resting heart rate < 60 bpm prior to treatment, severe hepatic impairment, pacemaker dependence (heart rate maintained exclusively by the pacemaker) and concomitant use of strong cytochrome P450 3A4 (CYP3A4) inhibitors.

  • Fetal Toxicity: Corlanor® may cause fetal toxicity when administered to a pregnant woman.
  • Atrial Fibrillation: Corlanor® increases the risk of atrial fibrillation. The rate of atrial fibrillation in patients treated with Corlanor® compared to placebo was 5% vs. 3.9% per patient-year, respectively.
  • Bradycardia and Conduction Disturbances: Bradycardia, sinus arrest and heart block have occurred with Corlanor®. Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsades de pointes, especially in patients with risk factors such as use of QTc prolonging drugs.  Concurrent use of verapamil or diltiazem also increases Corlanor® exposure and should be avoided. Avoid use of Corlanor® in patients with 2nd degree atrioventricular block unless a functioning demand pacemaker is present.
  • Adverse Reactions: The most common adverse drug reactions reported at least 1% more frequently with Corlanor® than placebo and that occurred in more than 1% of patients treated with Corlanor® were bradycardia (10% vs. 2.2%), hypertension or increased blood pressure (8.9% vs. 7.8%), atrial fibrillation (8.3% vs. 6.6%), and luminous phenomena (phosphenes) or visual brightness (2.8% vs. 0.5%). In postmarketing experience, torsades de pointes has been observed.

Please contact Amgen Medinfo at 800-77-AMGEN (800-772-6436) regarding Corlanor availability or find out more information, including full Prescribing Information and Medication Guide at and

About Amgen in the Cardiovascular Therapeutic Area
Building on more than three decades of experience in developing biotechnology medicines for patients with serious illnesses, Amgen is dedicated to addressing important scientific questions to advance care and improve the lives of patients with cardiovascular disease, the leading cause of morbidity and mortality worldwide.3 Amgen’s research into cardiovascular disease, and potential treatment options, is part of a growing competency at Amgen that utilizes human genetics to identify and validate certain drug targets. Through its own research and development efforts, as well as partnerships, Amgen is building a robust cardiovascular portfolio consisting of several approved and investigational molecules in an effort to address a number of today’s important unmet patient needs, such as high cholesterol and heart failure.

About Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

For more information, visit and follow us on

Forward-Looking Statements
This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on  Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project.  Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. Even when clinical trials are successful, regulatory authorities may question the sufficiency for approval of the trial endpoints we have selected. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market.

Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to acquire other companies or products and to integrate the operations of companies we have acquired may not be successful. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all. We are increasingly dependent on information technology systems, infrastructure and data security. Our stock price is volatile and may be affected by a number of events. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock.

The scientific information discussed in this news release relating to new indications is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration or European Commission for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses.

CONTACT: Amgen, Thousand Oaks
Kristen Davis, 805-447-3008 (Media)
Kristen Neese, 805-313-8267 (Media)
Arvind Sood, 805-447-1060 (Investors)


  1. Repatha® U.S. Prescribing Information. Amgen.
  2. Corlanor® U.S. Prescribing Information. Amgen.
  3. World Health Organization. Cardiovascular diseases (CVDs) fact sheet. Accessed July 2017.






Global Germanium Tetrachloride (GeCl4) Market to Gain From Constant Technological Advancements in the Industry From 2016 to 2021: Radiant Insights, Inc.

Germanium tetrachloride is a particular liquid possessing a strange sharp smell and has a colorless nature. The molecular formula of the particular compound is GeCl4. It is extensively employed in manufacturing purified germanium metal. It is said to be transparent to infrared light, thereby proving quite useful in the production of optical materials. In addition, it also plays a vital role as a semiconductor, alloying agent, as well as a reagent for carrying out the production of fiber optics for telecommunications. Due to its increased employment and benefits, the Germanium Tetrachloride Market is gaining huge recognition across various sectors.

The key factors that are responsible for the market growth may include technological advancements, constant innovations, rising benefits and applications, rise in the industrialization, burgeoning demands across various sectors particularly semiconductor and fiber optics sector, and rise in the investments by the leading manufacturers.

Owing to all the above-mentioned factors, it has been estimated that the Germanium Tetrachloride Market will experience a huge upsurge in the forthcoming years.

Germanium Tetrachloride Market is segmented on the basis of geographical region as 

  • North America
  • Southeast Asia
  • Europe
  • Japan
  • India
  • China

Access full report with TOC on Global Germanium Tetrachloride Market available with Radiant Insights, Inc. @:

As far as the geographical region is concerned, North America is lately dominating the market and it is estimated that the region will witness a huge upsurge in the forthcoming years, the reason being industrialization, technological advancements, rising applications, presence of large-scale companies, and rise in the investments by the leading manufacturers.

In contrast, Asia Pacific and Europe are also coming up as one of the promising regions in the upcoming years owing to rise in the market growth opportunities, developing economies, and constant advancements.

The prominent participants operating in the Germanium Tetrachloride Market are recognized as 

  • Yunnan Chihong Zinc and Germanium Co., Ltd
  • Indium Corporation. Japan Algae Co., Ltd.
  • Novotech, Inc.
  • Photonic Sense GmbH
  • PPM Pure Metals GmbH
  • Teck Resources Limited, Umicore SA
  • Umicore Electro-Optic Materials
  • Voltaix, LLC
  • Yunnan Lincang Xinyuan Germanium Industry Co., Ltd.
  • Chemical and Technical Developments Ltd
  • GFI Advanced Technologies Inc.

Browse reports of similar category available with Radiant Insights, Inc.:

About Radiant Insights, Inc.:

At Radiant Insights, we work with the aim to reach the highest levels of customer satisfaction. Our representatives strive to understand diverse client requirements and cater to the same with the most innovative and functional solutions.

Michelle Thoras.
Corporate Sales Specialist
Radiant Insights, Inc.
Phone: +1-415-349-0054
Toll Free: 1-888-928-9744


SOURCE Radiant Insights, Inc.

Pharmaceutical Fine Chemicals Market Worth $153.7 Billion by 2025: Grand View Research, Inc.

The global pharmaceutical fine chemicals market is expected to reach USD 153.7 billion by 2025, according to a new report by Grand View Research, Inc. Increasing demand for preventive healthcare is expected to be a major factor driving market growth. Utilization of pharmaceutical fine chemicals (PFCs) has increased on account of the increasing aging population across the globe.

(Logo: )

Cardiovascular is anticipated to the fastest growing application segment over the over the next eight years growing at an estimated CAGR of 8.4%. The occurrence of cardiovascular disease is on the rise owing to the unhealthy lifestyle of human beings. According to the World Health Organization (WHO), cardiovascular diseases are considered to be the prime cause of fatalities across the globe. The organization also states that cardiovascular diseases caused the death of approximately 17.7 million people in the year 2015. This number approximately represented 31% of the total deaths in the year 2015.

Obesity and an unhealthy lifestyle are some of the most important factors which lead to the occurrence of various diseases such as cardiovascular, neurological, oncological, infectious diseases, metabolic system, diabetes, respiratory, gastrointestinal, and musculoskeletal disorders. Eating junk food, leading unhygienic lifestyle, irregular timetable and many other unhealthy habits lead to diseases amongst human beings. Studies also show that males have more chance of contracting diabetes as compared to females. All these factors combined are thus anticipated to propel the market growth over the forecast period.

Browse full research report with TOC on Pharmaceutical Fine Chemicals Market Analysis By Application (Cardiovascular, Neurological, Oncological, Diabetes, Respiratory, Gastrointestinal, Musculoskeletal), By Type, By Size, And Segment Forecasts, 2014 – 2025 at:

Further key findings from the report suggest:

  • The global pharmaceutical fine chemicals demand in terms of revenue was USD 78.2 billion in 2016 and is expected to grow at a CAGR of 7.9% from 2017 to 2025
  • Proprietary emerged as the largest type segment in 2016 and is estimated to generate revenue of USD 125.1 billion by 2025
  • Big molecules were the largest size segment in 2016 and is expected to grow at an estimated CAGR of 7.8% over the next eight years
  • Advanced intermediates is expected to be the fastest growing product segment over the forecast period growing at an estimated CAGR of 8.3%
  • Industry participants include Angelini Acraf S.p.A, Albermarle Corporation, Chemada Fine Chemicals, W.R. Grace & Co., and Kenko Corporation. These players have vertically integrated their operations to increase their market presence and thus gain competitive advantage in the market

Browse related reports by Grand View Research:

Grand View Research has segmented the global pharmaceutical fine chemicals market on the basis of application, type, size, product, and region:

  • Pharmaceutical Fine Chemicals Application Outlook (Revenue, USD Billion, 2014 – 2025)
    • Cardiovascular
    • Neurological
    • Oncological
    • Infectious diseases
    • Metabolic system
    • Diabetes
    • Respiratory
    • Gastrointestinal
    • Mucoskeletal
    • Others
  • Pharmaceutical Fine Chemicals Type Outlook (Revenue, USD Billion, 2014 – 2025)
    • Proprietary
    • Non-proprietary
  • Pharmaceutical Fine Chemicals Size Outlook (Revenue, USD Billion, 2014 – 2025)
    • Small molecules
    • Big molecules
  • Pharmaceutical Fine Chemicals Product Outlook (Revenue, USD Billion, 2014 – 2025)
    • Basic building blocks
    • Advanced intermediates
    • Active ingredients
  • Pharmaceutical Fine Chemicals Regional Outlook (Revenue, USD Billion, 2014 – 2025)
    • North America
      • U.S.
    • Europe
      • Germany
      • UK
    • Asia Pacific
      • China
      • India
      • Japan
    • Central & South America
    • Middle East & Africa

Read Our Blog By Grand View Research:

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: +1-415-349-0058
Toll Free: 1-888-202-9519



SOURCE Grand View Research, Inc.

Global Sterilization Equipment Market Size to Witness Growth at CAGR Exceeding 9% From 2014 To 2025: Million Insights

The global sterilization equipment market size was worth USD 4.3 billion in 2016 which is anticipated to grow at a CAGR of more than 9.5% during the forecast period. Various factors, which led to such huge market growth, include increase in the aging population, rise in the number of surgeries conducted, and surging incidences of chronic diseases. Also, there are number of changes in the government policies and regulations which in a way is helping the sterilization equipment market to grow and advance. Such changes in the policies have resulted in increase in the adoption of sterilization equipment by various hospitals and diagnostic centres.

Similarly, increase in the number of government initiatives, which are stringent enough to ensure utmost quality of the product, is making way for the sterilization equipment market to grow. Advancement in technologies of sterilization equipment such as gamma ray filtration, radiation, microfiltration and many more have created wide scope for sterilization equipment in the food industry.

The heat sterilization technique captured the largest market share in 2016 in which hydrated state is preferred more than dry state due to its greater reliability in use. It is estimated that the low temperature market segment is expected to grow at the highest CAGR due to compatibility with thermo-labile products, lesser complex in handling and monitoring. The introduction of various advancements in technology of the equipment for sterilization technique has led to better business expansion and penetration to various regions around the globe.

The hospital segment captured the largest market share in the year 2016, due to growing infection burden, rising number of surgeries performed, advancing technologies and rise in the number of patients being admitted. The ever-increasing need for quality assurance and quality control by pharmaceutical company in its manufacturing and storage processes resulted it to be the second largest segment in the global market.

Browse full research report with TOC on Sterilization Equipment Market Size & Forecast Report, 2014 – 2025 at:

North America dominated the sterilization equipment industry having largest revenue share in 2016. Increasing incidences of disease caused by a number of infections, rise in the use of reusable surgical equipment, greater advancement in technology is leading to greater market share of the region.

Some of the top companies operating in this industry are STERIS Corporation; Advanced Sterilization Products Services, Inc.; Getinge Group; 3M; Cantel Medical; Belimed; and others.

A huge pool of companies is focused towards advancing the sterilization equipment technology after thorough research and development in this sector. The most common strategy opted by companies are through mergers acquisitions and collaboration in order to gain the maximum market share in the industry.

Browse reports of similar category available with Million Insights:

  • Air Ambulance Services Market – Global air ambulance services market size was worth USD 3.7 billion in 2016 which is anticipated to grow at a CAGR of more than 9.3% during the forecast period.
  • Pen Needles Market – Global pen needles market was valued at USD 1.5 billion in 2015, which is projected to grow at a CAGR of more than 13.0% during the forecast period.
  • Orthopedic Braces and Supports Market – Global orthopaedic braces and supports market size was worth USD 3.1 billion in 2015 which is anticipated to grow at a CAGR of more than 6.7% during the forecast period.
  • Ophthalmic Lasers Market – Global ophthalmic lasers market size was worth USD 1.0 billion in 2016, which is anticipated to grow at a CAGR of more than 5.9% during the forecast period.

Market Segmentation:

Sterilization equipment Technique Outlook (Revenue, USD Million, 2014 – 2025)

• Heat sterilization

• Low-temperature sterilization

• Filtration sterilization

• Radiation sterilization

• Liquid sterilization

Sterilization equipment End-user Outlook (Revenue, USD Million, 2014 – 2025)

• Hospitals

• Pharmaceutical companies

• Medical devices companies

• Clinical laboratories/research centers

• Others

Sterilization equipment Regional Outlook (Revenue, USD Million, 2014 – 2025)

• North America

• U.S.

• Canada

• Europe

• Germany

• UK

• Asia Pacific

• China

• Japan

• Latin America

• Brazil

• Mexico


• South Africa

About Million Insights:

Million Insights, is a distributor of market research reports, published by premium publishers only. We have a comprehensive market place, that will enable you to compare data points, before you make a purchase. Enabling informed buying, is our motto and we strive hard to ensure that our clients get to browse through multiple samples, prior to an investment. Service flexibility & the fastest response time are two pillars, on which our business model is founded. Our market research report store, includes in-depth reports, from across various industry verticals, such as healthcare, technology, chemicals, food & beverages, consumer goods, material science & automotive.

Ryan Manuel
Research Support Specialist, USA
Million Insights
Phone: +1-408-610-2300
Toll Free: +1-866-831-4085



SOURCE Million Insights

EasyRentCars is Leading the Online Luxury Car Rental Trend

If you’re planning to spend memorable holidays in the now offers the opportunity to be at the wheel of the supercar you have always dreamed of.

From August 21st, the exotic, sports, American muscle and ultra luxury car collections of Beverly Hills Rent-A-Car (BHRAC) are officially available for booking on The Audi R8, Bentley GTC, Ferrari 488, Lamborghini Huracan are only a few of the luxurious series available in different US locations, including Las VegasSan Francisco and Los Angeles.

Most countries’ travelers, car rental companies and tour operators assert that high-end vehicles are in high demand in the USA, notably thanks to the country’s developed economy and road network, as well as its strong touristic appeal. The country is host to several iconic road trip’s itineraries, such as the California State Route 1, Route 66, Highway 61, US route 20 and 30. With its brand new range of premium offers, aims at providing exciting and reliable solutions to the growing demand of high-end vehicles in the USA.

Growing Market Trends in Car Rental

On a global scale, the luxury car rental market is expected to witness significant growth due to the increasing tourism industry and demand for high-end vehicles. According to Technavio’s Global Car Rental Market report (2016-2020), the luxury car rental market was valued at $9.92 billion in 2015 and is predicted to double and reach $19.66 billion by 2020, suggesting a rapid demand growth worldwide.

Similar rapid growth is estimated for the car rental industry as a whole, which is expected to grow along international tourism. Concretely, about 55 million more tourists traveled abroad in 2016 compared to 2015. Among different countries and regions, other than APAC, Europe and North America, the car rental market in ROW (Rest of World, especially Middle East) shows particular potential. It was valued at $4.94 billion in 2015 and is predicted to reach $10.48 billion by 2020, growing at a CAGR (Compound Annual Growth Rate) of 13.82%.

EasyRentCars Try

On top of growing international tourism, increasing global Internet penetration is another key factor explaining the growth of the car rental industry. Global Internet penetration increased from 29% in 2010 to 41% in 2014. As a consequence, technology service providers and operators have been enhancing their Internet-based and mobile services to create and meet demand. is operating in accordance with the international tourism and Internet penetration growth described above, and provides optimized and easy online car rental solutions worldwide. With its ergonomic interface in both website and APP, easy cancellation program and lowest price guarantee, aims at enabling you to enjoy a perfect booking and driving experience.

Check it out on Facebook or on Trustpilot!

Photo –
Photo –


SOURCE EasyRentCars

CONTACT: Lv Yin, +86-183-2013-2179,

Suning’s 8.18 Shopping Spree Hits Online Sales Growth of 263% Showing Demand for High-quality Products of Global Brands among Chinese Consumers

The newly listed company of Fortune Global 500, Suning Commerce Group, owned by China’s retail giant, Suning Holdings Group (known as “Suning” or “the Group”), recently hosted one of the most remarkable shopping sprees in China this August both on its online and offline platforms. (Both the online and offline sales have increased 263% and 107% separately compared to the ones of last year, and the completion rate of same-day delivery hits 96.5%.) The event also shows that Suning is playing a significant role in promoting international brands as the country’s consumers are seeking authentic high-quality products all over the world.

Known as the “8.18 Shopping Festival”, the online-to-offline sale event is created by Suning in 2014 and then became a fixture on its retail calendar every year. The half-month shopping spree lasts from August 1st to 18th features discounts and promotion campaigns in the Group’s domestic and international retail channels, including nearly 4,000 self-operated bricks-and-mortar stores and its ecommerce platform, which ranks as the top three Chinese B2C platforms with 500 million users.

Zhang Jindong, chairman of Suning Holdings Group, noted that through the shopping spree, Suning makes high-quality products the most accessible to consumers with best services. It demonstrated that the Group aims to introduce more fine products around the globe to the Chinese market.

For global retailers who want to enter the Chinese market or reach more Chinese consumers, there are three new noteworthy consumption trends from analyzing data gathered through Suning’s ecommerce platforms during the shopping spree event, especially its international site that sells a wide range of products directly purchased from retailers or suppliers around the world.

The first one is a focus on healthcare and childcare products from AustraliaNew Zealand and European countries, such as original food produce and baby formula milk. It shows that now Chinese consumers pay more attention on healthy eating habits than before and are willing to plunk down large money for authentic high-quality products. Among all the spree shoppers this year, female shoppers showed the largest interest for cosmetics from the United StatesJapanSouth Korea and European countries.

The two findings together demonstrate that there is an upgrade in Chinese consumers’ consumption level and capability. They start to adopt the middle-class lifestyle by focusing on things that can improve their life quality.

Big names in upscale personal care electronics have made a lot of orders, including Dyson, Phillips, Braun and Panasonic. Fine wines from Treasury Wine Estates, with which Suning has entered a strategic partnership, were also snapped up by shoppers. For the first time this year, Suning offers speedy delivery with its strategic partner for fresh products, such as cherries from the US, beef from Australia and Seafood from South America, in 180 cities in China, a staggering rise from last year’s 17.

Suning’s “8.18” shopping spree is not only the reflection of China’s booming ecommerce sector, but also a showcase of the retailer’s ability to serve international merchants and domestic consumers. According to Zhang, service is always the core business. Capitalizing on its sophisticated direct purchase, warehousing and delivery systems, a “Smart Retail” model that integrates online and offline services, as well as the Group’s resources in six industries including Retail, Real Estate, Financial Services, Media and Entertainment, Sports and Investment, Suning aims to better serve the upgrading needs of Chinese consumers.

About Suning Holdings Group

Founded in 1990, Suning is one of the leading commercial enterprises in China with 180,000 employees and two listed companies in China and Japan. In 2016, with the annual revenue of 51.27 billion USD (350.288 billion RMB), Suning Holdings Group ranks the second place of non-state owned enterprises in China. With the mission of “Leading the Industrial Advancement in Creating a Higher Quality of Life for All”, Suning strives to continue its rapid growth across six vertical industries including Retail, Real Estate, Financial Services, Media and Entertainment, Sports and Investment.

SOURCE Suning holdings group

CONTACT: Lyrin Lin, Brand Manager, Mobile: +86-186-5166-7227, Email:

SY Lau, Chairman of Tencent Advertising: A modern, Big Data-based advertising era is coming

Following Tencent’s structural adjustments, Tencent’s Senior Executive Vice President SY Lau, who has always been in the limelight, was given a new title.  He was appointed as Tencent’s Chairman of advertising and Chairman of group marketing and global branding. Lau’s responsibilities will be coordinating advertising business with other sectors in the company. This will enhance Tencent’s branding influence in the global market, and help develop strategic cooperation with international partners. For Tencent, a company whose market value has pushed it into the world’s top ten through recording breaking share prices, the appointment of Lau will strengthen Tencent’s strategic power in digital entertainment and information, while further combining content and technology.

SY Lau stands as witness to an unprecedented new opportunity for China’s Internet advertising industry. In the United States, 40% of the market share in advertising comes from online advertising. In China, this portion could reach 64% this year. In the U.S, social advertising takes about 20% of the whole online advertising pie, while in China, social advertising only takes about 8%-9%, and more than 50% of that comes from TencentTencent has an incredibly huge market potential.

SY Lau joined Tencent in 2006 and experienced Tencent’s golden ages when the business skyrocketed. Taking Tencent advertising as an example, in 2006, online advertising revenue was 267 million yuan. Under Lau’s leadership, the revenue reached 27 billion yuan in 2016, a hundred-fold increase in Tencent’s advertising revenue in only one decade. Lau’s excellent achievements placed him into the “The World’s 21 Most Influential People in Marketing and Media” list by American magazine “Advertising Age” in 2011. Lau was also the first Chinese to win “Media Person of the Year” awarded by The Cannes Lions Festival in 2015. Additionally, he is a member of the Asia Pacific Advisory Board (APAB) of Harvard Business School.

“The advertising industry is going through drastic changes”, said SY Lau. If we look at the trend, on the one hand, cost-per-action (CPA) advertisement is growing fast. On the other hand, the growth speed of branding advertisements is slowing down. With regards to newsfeed advertising, cost-per-time (CPT) advertising is switching to cost-per-action. There’s a great demand for news aggregation advertising. This has huge business potential. Short-form video advertising has also become a global trend on social media.

“I think what all of the internet companies agree on is that this is an era of algorithms”, said Lau. “A modern Big Data-based era of advertising is coming.” Algorithm-based intelligent push and newsfeed advertising is the mainstream model for Internet cost-per-action (CPA) advertising. Statistics also prove that: China’s mobile newsfeed advertising brought almost 4 billion dollars of revenue in 2016, a 110% growth rate over the year before. This revenue is expected to reach 6.6 billion dollars in 2017.

In Lau’s opinion, advertising in Tencent is significant in two ways. One is the value it brings for the stockholders as a stable source of revenue. The other is to work as a “connector”, which combines different businesses through advertising. Tencent hopes to enable the advertisers with such platforms.

“The future of Tencent advertising is to fully embrace social network, video and mobile advertising. What I care about most is the coverage, as well as the penetration and retention rate”. Lau said the future directions of Tencent advertising’s integration lies in: First, providing a comprehensive solution for big clients, combining branding and performance-based advertisements to achieve high penetration rates. Second, for long tail clients, raise the amount of small and regional advertisers by optimizing and upgrading sales management and self-service tools to value advertising efficiencies.

Tencent needs to achieve the following in order to integrate advertising into its business, said Lau. “First, we need to resist loneliness, and build upon past success but start from zero again. Second, different parallel sectors need to communicate with each other. Third, Tencent has to switch its mindset from ‘to C’ to ‘to B'”.

Click the following link to view the complete interview by Financial Times’ “LUNCH WITH FT”.

Grace Tang
Tencent Corporate Marketing & PR Department

SOURCE Tencent

SPJIMR Only Indian B-School in AACSB’s 2017 List of ‘Innovations That Inspire’

Recognised for engaging a diverse community through the innovative Post Graduate Management Programme for Women (PGMPW)

Association to Advance Collegiate Schools of Business (AACSB), the US-based accreditation body, has named SPJIMR as one of the 35 innovative global schools for engaging a diverse community through its innovative Post Graduate Management Programme for Women (PGMPW).

(Photo: )

“With great pleasure, I am thrilled to recognise SPJIMR for its role in driving innovation in business education and fostering positive change in the areas of diversity and global economic prosperity,” said Tom R. Robinson, President and Chief Executive Officer of AACSB International.

“Through meaningful ideas and increasing opportunities for engagement, SPJIMR has created a remarkable impact, to ensure a better and more connected world for many years to come,” added Tom R. Robinson.

This is the second consecutive year that SPJIMR is the only B-School from India that has been named among select global schools noted for ‘Innovations That Inspire’. The citation this year came to SPJIMR for its innovative academic initiative, the PGMPW, which launched its maiden batch of 20 women participants earlier in the year. The programme is designed to meet the needs of women leaders and managers who are ready to return to their careers after a break.

AACSB received a pool of 315 submissions, spanning 33 countries and 188 institutions. It picked SPJIMR and 34 other innovative schools to be applauded for the remarkable efforts underway to transform business education for the betterment of all.

The innovative schools were cited under three categories: Engagement Across Disciplines, Engagement With Business and Engaging A Diverse Community.

SPJIMR earned the citation under the category ‘Engaging A Diverse Community’ for the PGMPW, a programme that includes personalised mentoring and intensive industry partnerships to prepare talented Indian women, who have taken a mid-career break, to return to leadership positions.

As AACSB put it, “We highlight outstanding schools that challenge the status quo through forward looking curriculum that prepares the future leaders of tomorrow while tackling the most pressing challenges of today.”

Dr. Ranjan Banerjee, SPJIMR Dean said, “We are trying to make a difference in the important aspect of building women leaders of tomorrow. The award is a timely recognition of the dedication and creativity of our faculty and staff.”

AACSB says it connects educators, students, and business to achieve a common goal of creating the next generation of great leaders. Since 1916, AACSB has been providing quality assurance, business education intelligence and professional development services to more than 785 accredited business schools worldwide.


S.P. Jain Institute of Management & Research (SPJIMR) ( is a constituent of the Bharatiya Vidya Bhavan and is ranked among the top ten business schools of India. As a premier school of management, SPJIMR is noted for pedagogic innovations and pioneering programmes, which have helped the Institute stand out for its unique and distinctive path in management education. The philosophical pillars upon which rests the edifice of SPJIMR’s educational pedagogy and development are ‘influencing practice’ and ‘promoting value-based growth’. SPJIMR currently operates only from its 45-acre campus in Andheri, Mumbai. To avoid confusing us with any other institution, look for the five strokes logo and the Bharatiya Vidya Bhavan association.

Media Contact:
Prof. Abbasali Gabula
Deputy Director
External Relations & Administration
S.P. Jain Institute of Management and Research (SPJIMR)


SOURCE S.P. Jain Institute of Management & Research

BrokerNotes: Why Modern Traders Are Just Your Average Joanne

Trading is no longer exclusively a glamorous boys’ club, according to a new report by broker comparison site, BrokerNotes.

(Photo: )

The report breaks down the demographics of the 9.6 million online traders to reveal the common attributes of the modern trader.

The traditional image of men in sharp suits, earning astronomical salaries, and driving super-fast luxury cars is fading. With the advent of online trading platforms, trading has become accessible to virtually anyone with an Internet connection. This has led to one of the biggest shifts in the types of people participating in the markets. In their report, BrokerNotes have uncovered that:

  • Over 50% of UK online traders earn less than £35k per year
  • Almost 50% of UK online traders drive a basic car or have no car at all
  • The majority of online traders are young adults, and their numbers are increasing
  • 1 in 10 UK online traders are female and their numbers are on the rise

Average UK Online Trader Earns £38,700 Per Year

The average income for online traders is a modest £38,700 per annum, with the highest proportion of traders falling in the £20k to £25k earnings bracket. The report also revealed that less than 0.3% of UK traders own a luxury vehicle, such as a Lamborghini: a quarter of traders drive a basic car, with a fifth owning no car at all.

Trading Attracts Growing Number of Young Adults

According to the study, a rising proportion of online traders are under the age of 35. Brokers have tapped in to this growing market with useful tools such as social and copy trading, which allow inexperienced clients to follow the trades and strategies of more knowledgeable traders. The younger demographic are also potentially being attracted by cryptocurrencies such as Bitcoin.

Female Traders Attracted by Modern Trading Strategies

Whilst it is clear that the trading arena is still dominated by men, there is growing evidence that women are breaking into the industry. 42% of women classed themselves as experienced, and studies suggest that women commonly engage in more successful trading strategies than men.

Marcus Taylor, founder and CEO at BrokerNotes, said, “We are witnessing a transitional period in trading, with easy to use, online platforms facilitating a rise in novice traders. The industry has become better regulated to accommodate the new participants, with more services and controls being introduced to offer them the necessary support and protection.”

BrokerNotes was launched in 2014 to help traders compare and find the most suitable, reputable brokers to meet their needs. For more information, and to view the full report, visit

Media Contact:
Ryosei Kurihara
Marketing Manager

SOURCE BrokerNotes

Hitachi Launches New TX Series Escalator for India, Asia and the Middle East

Hitachi, Ltd. (TSE: 6501, “Hitachi”) and Hitachi Building Systems Co., Ltd. today announced the launch of the new TX Series escalator for Hong Kong.

In July 2016, Hitachi integrated its escalator businesses of Japan and China, consolidating its resources and enhancing its business operations in both countries, centered around its key business location in Guangzhou, China. The new TX Series escalator launched by Hitachi is a model that meets multiple standards in ChinaIndiaAsia and the Middle East. The model follows the same concept for the machine room-less elevator for Asia and the Middle East which was launched in September 2016. In addition to conforming to Chinese and European safety and quality standards for escalator equipment, the TX Series will be manufactured in accordance with Hitachi’s own strict standards of safety and quality, adhering to safety standards in all other regions. It also adopts a functional design based on the concept of an escalator that fits closely with the unconscious actions of users, in the pursuit of their ease and comfort.

The TX Series offers flexibility with a selection of various product specifications, as well as its excellent design and safety features, designed to cater to a diverse range of customer needs. It also saves space required for the installation, covering a smaller area in comparison with existing products*1.

Hitachi will begin sales of the TX Series in ChinaIndiaAsia and the Middle East, and aims to receive orders of 10,000 units in 2018.

  • Features of the TX Series
  1. Safety
    The TX Series offers various new safety features designed with optimal user safety in mind. The side portions of the steps are 8 mm higher than the central portion to prevent accidents in which a users’ shoe can become caught between the step and the skirt (side wall) of the escalator. The new TX series has also been fitted with brushes located at foot level on the left and right skirts to let users know if their foot comes into contact with the side walls. A special finish has also been adopted for the landing plates at the entry and exit points of the escalator to prevent users from slipping when getting on and off the escalator.
  2. Design
    The TX Series adopts a simple and functional design that offers the smoothness, safety and comfort that users unconsciously expect to experience when riding an escalator. For example, by minimizing the size of the metal frame supporting the escalator’s balustrades, the TX Series’ design maximizes the size of the glass surfaces, and achieves greater simplicity at the entrance and exit points (landings) by reducing the number of recesses and protrusions around the hand rail. Additionally, by expanding the installation space of the light fixture, the TX Series also enables enhanced lighting options for illuminating the entire surroundings of the balustrades.
  3. Space saving
    By shortening the span dimensions*2 by 150 mm, the TX Series has made it possible to install escalators in more confined spaces where installation presents difficulties with conventional product designs.

*1 The made-in-China escalator, “SX series“, which is previous model of “TX series“.
*2 The span between the beam on upper floor and that on the lower floor of the escalator when the escalator is installed.

  • Specification Overview of TX Series

Balustrade width (Step width)

Angle of elevation


1,200mm (1,000mm),

1,000mm (800mm)

30 degrees, 35 degrees

30m per minute

About Hitachi, Ltd.

Hitachi, Ltd. (TSE: 6501), headquartered in Tokyo, Japan, delivers innovations that answer society’s challenges. The company’s consolidated revenues for fiscal 2016 (ended March 31, 2017) totaled 9,162.2 billion yen ($81.8 billion). The Hitachi Group is a global leader in the Social Innovation Business, and it has approximately 304,000 employees worldwide. Through collaborative creation, Hitachi is providing solutions to customers in a broad range of sectors, including Power / Energy, Industry / Distribution / Water, Urban Development, and Finance / Government & Public / Healthcare. For more information on Hitachi, please visit the company’s website at

Photo –
Photo –

SOURCE Hitachi(China)Ltd

CONTACT: Lisa Zhang, +86-10-59211099,


Telit Announces World’s First Category 11 LTE Full Mini PCIe Card

Telit, a global enabler of the Internet of Things (IoT), today announced the LM940, the world’s first global Full PCI Express Mini Card (mPCIe) module for the router and gateway industry supporting LTE Advanced Category 11 (Cat 11) with speeds of up to 600 Mbps, available with various mobile network operator approvals in the fourth quarter of 2017. For more information on the LM940 mPCIe module, visit:

The only enabling technology in an mPCIe form factor to support Cat 11 with the Snapdragon X12 LTE modem, the industrial-grade LM940 delivers significant flexibility and a competitive edge to original equipment manufacturers (OEM) looking to quickly deploy next generation products with an unrivaled user experience.

Today, customers of router and gateway OEMs demand additional bandwidth and near instant network response times as applications like high definition video streaming with digital signage, commercial and enterprise failover needs and pop-up stores are becoming increasingly sophisticated.

“This industrial-grade module from Telit supporting LTE Cat 11 with global coverage will be very attractive for equipment manufacturers looking to deploy the latest solutions now, especially in the router and gateway marketsupporting high-bandwidth dependent applications like digital signage,” said Sam Lucero, senior principal analyst for IHS Markit, a global information provider. “As detailed in our June 2016 report on the industrial cellular IoT gateways market*, IHS Markit anticipates gateway shipments will rise from nearly two million shipped in 2016 to more than six million shipped in 2021. The value of these industrial cellular IoT gateways shipped in 2021 will slightly exceed USD $1.6 billion.”

“Telit extends its leadership again by delivering customers the latest releases in LTE Advanced technology that they can take to market today,” says Manish Watwani, VP Global Product Marketing for Telit. “The LM940 is the only global product for the router and gateway segment that allows OEMs to immediately leverage the 3x carrier aggregation and the higher order modulation of the 256 QAM capabilities currently available amongst most mobile operator networks. Combined with an exceptional power efficiency platform, this is by far the ideal solution to enable commercial and enterprise applications in the router industry, such as branch office connectivity, LTE failover, digital signage, kiosks, pop-up stores, vehicle routers, construction sites and more.”

“The Snapdragon X12 LTE modem with LTE Advanced technologies providing peak download speeds of 600 Mbps, defines a new level of service for emerging applications,” says Gautam Sheoran, director, product management, Qualcomm Technologies, Inc. “We are pleased with our ongoing collaboration with Telit to bring technologies that enable emerging applications like 4K video, virtual reality and cognitive computing to the global market.”

Additional Technical Features:

  • LTE Category 11 LTE Cat. 11 DL / Cat. 5 UL Rel.10
    • 3x Carrier Aggregation leverages extended capabilities of the network for increased coverage and bandwidth
    • Up to 600 Mbps DL w/3x Carrier Aggregation and 256 QAM
    • Up to 75 Mbps UL w/ 64QAM
  • HSPA+ Rel. 8
  • Quad-constellation integrated GNSS
  • Popular mPCIe form factor (50.95 x 30 x 2.8 mm)
  • Temperature range: -40 to 85° C
  • Linux and Windows driver support

For more information and samples, contact Telit:

Download LM940 mPCIe module image:

* Information based on IHS Markit Technology Group, Cellular IoT Gateways, June 2016. Information is not an endorsement of Telit. Any reliance on these results is at the third party’s own risk. Visit  for more details.

About Telit
Telit (AIM: TCM), is a global leader in Internet of Things (IoT) enablement.  The company offers the industry’s broadest portfolio of integrated products and services for end-to-end IoT deployments – including cellular communication modules in all technologies, GNSS, Wi-Fi, short-to-long range wireless modules, IoT connectivity plans and IoT platform services. Through the IoT Portal, Telit makes IoT onboarding easy, reduces risk, time to market, complexity and costs for asset tracking, remote monitoring and control, telematics, industrial automation and others, across many industries and vertical markets worldwide.

Copyright © 2017 Telit Communications PLC. All rights reserved. Telit and all associated logos are trademarks of Telit Communications PLC in the United States and other countries. Other names used herein may be trademarks of their respective owners.

Qualcomm and Snapdragon are trademarks of Qualcomm Incorporated, registered in the United States and other countries.

Qualcomm Snapdragon is a product of Qualcomm Technologies, Inc.

Telit Media Contact:
Leslie Hart




Truecopy Launches GST-compliant DSC Token Signer for Invoices and Filings

Truecopy Credentials Pvt. Ltd., a company specializing in digital document authentication announced the next version of its DSC Signer that enables bulk-signing of documents using DSC tokens complying with GST guidelines. The DSC Signer has so far been used to sign millions of documents by numerous users across industry verticals.

(Photo: )

“The DSC Signer  has emerged as the application of preference for industry users who want to digitally sign documents. With this next version, we make it simpler for our clients to use it, and provide a higher level of functionality and security features,” said Sonia Soman, CEO of Truecopy Credentials.

In a corporate setting, Truecopy’s solutions are already being used to minimize costs associated with printing, mailing, archival and retrieval of paper documents. Applications of digital signatures include invoices, bills, contracts, purchase orders, employee letters, and other HR and Financial documents. With the GST law coming into effect, it has become mandatory for companies to digitally sign GST filings and invoices. DSC Signer will facilitate invoice signing by companies and signing of filings for GSPs and ASPs. Whether it is a large company, SME or a professional like a chartered accountant/consultant/architect, the DSC Signer is useful for the user.

“It takes only a few minutes to make the transition to digital signatures. Simply download, install and run the application to sign one PDF file at a time or sign thousands of documents in bulk. It is a simple yet it is a must have application for anyone who is physically signing papers today,” she added.

The company sees digital signatures playing a key role in the elimination of paper documentation and adoption of environmentally friendly practices in the future. As India moves towards a paperless world, digital signatures would form a cornerstone of that movement.

About Truecopy Credentials Pvt. Ltd.:

Truecopy Credentials Pvt. Ltd. is a leading provider of document authentication solutions using digital signatures. Over 300 clients including financial institutions, educational institutions and companies in India use Truecopy to benefit from the cost savings and the convenience it provides. For more information visit us at or write to us at

Media Contact:
Sonia Soman
Truecopy Credentials Pvt. Ltd.


SOURCE Truecopy Credentials Pvt. Ltd.

Scoot spreads its wings into new markets with Worldpay

Scoot Tigerair Pte. Ltd. (Scoot), the low-cost airline indirect subsidiary of Singapore Airlines Limited (SIA), has selected Worldpay as its exclusive payments provider. On the 25th July 2017 Scoot Pte. Ltd. and Tiger Airways Singapore Pte. Ltd. amalgamated to become one entity under the name Scoot Tigerair Pte. Ltd.

Following the amalgamation, Scoot sought a strategic payments provider that could help grow its international and long-haul business as a new integrated brand, particularly in key global markets such as Asia Pacific and EMEA.  As a leader in card payments with truly global coverage, Worldpay was ideally placed to deliver an end-to-end payments solution to improve the customer experience and ultimately sell more online tickets to travellers. Since partnering with Worldpay, the airline has seen payment acceptance rates soar to 90% across all markets.

With extensive experience in the airline industry, Worldpay offers a wealth of expertise in managing the complexities of international eCommerce, including supporting online payments in multiple currencies, optimising the booking process, and integrating with multiple global distribution systems. Worldpay is also enabling Scoot to accept a growing range of payment methods favoured by travellers across the region, including Alipay and China Union Pay in China, Konbini in Japan, and POLi Payments and PayPal in Australia.

New data analytics capabilities will also see Scoot able to unlock the value of its payments data for the first time, and by selecting Worldpay as its exclusive payments provider, the low cost carrier will also save time and resources by not dealing with multiple suppliers. With new insight from Worldpay, the brand is now able to optimise eCommerce business, increasing online sales, and identifying cost-saving opportunities.

Leslie Thng, Chief Commercial Officer at Scoot said: “We see Worldpay as the ideal partner to support our aggressive growth plan, and reduce our time-to-market into each new region. Our new SingaporeAthens route launched earlier this month, and with plans to launch five more new destinations in the next 12 months, we need a payments solution to support our global vision. We are delighted that our collaboration with Worldpay has been so successful, with a seamless on-boarding process and continuous support as we launch into new markets.”

Ng Long Jian, VP Finance, at Scoot added: “Working alongside Worldpay has given us a competitive edge in the market. By working with a single payment provider, we have been able to save time, money and resources as we expand our global network. Having such a wealth of data analytics at our fingertips has also been invaluable. With full visibility of our transaction history and consumer spending patterns, we have already been able to identify cost-saving measures to fine tune our online business.”

Stuart Thornton, VP Business Development APAC, Global eCom, Worldpay, commented:  “The global carrier market has never been more competitive, so it is vital that our customers optimise their online services as they expand internationally.  Singapore’s flagship airline group has embarked on an ambitious growth programme with its low-cost, long-haul offering. But by putting payments at the heart of its eCommerce strategy, Scoot has been able to cut costs, while increasing sales, helping to improve competitiveness and ensure sustainable profitability in an exciting yet challenging market.”

About Worldpay

Worldpay is a leading payments company with global reach. We provide an extensive range of technology-led payment products and services to around 400,000 customers, enabling their businesses to grow and prosper. We manage the increasing complexity of the payments landscape for our customers, allowing them to accept the widest range of payment types around the world. Using our network and technology, we are able to process payments from geographies covering 99% of global GDP, across 146 countries and 126 currencies. We help our customers to accept more than 300 different payment types.

For more information, visit

About Scoot

Scoot™, the low-cost, medium-to-long haul arm of the Singapore Airlines Group managed by Budget Aviation Holdings, has carried over seven million guests since taking to the skies in June 2012. The world’s first all 787 Dreamliner fleet operates between Singapore and SydneyGold CoastBangkokTaipeiTokyoTianjinShenyangNanjingQingdaoSeoulHong KongPerthOsaka, Kaohsiung, HangzhouMelbourneGuangzhouJeddahChennai, Amritsar, SapporoDalian and Athens. Scoot provides – in addition to fantastic value airfares — a safe, reliable and contemporary travel experience with a unique attitude — Scootitude™. Offering amenities including on-board Wi-Fi Internet connectivity and in-seat power as well as the ability to redeem and accrue Singapore Airlines KrisFlyer miles, Scoot was voted 2015, 2016 and 2017 Best Low Cost Airline (Asia/Pacific) by and ranked in the Top 10 of the World’s Best Low-Cost Airlines in 2015 by Skytrax. Scoot is passionate about changing the way people travel long distance.

For more information, please contact:

Global eCom



Emily Lahey, PR Director

+44 (0) 203 664 5663


Candy Xie

+1 (852) 2501 7949

SOURCE Worldpay

AgDevCo Invests in Ugandan Maize and Cassava Miller, Talian Company

AgDevCo, a social impact agribusiness investor, announces a $450,000 debt investment into a Ugandan milling business, Talian Company Limited. Talian Company is a family-run milling business producing quality maize and cassava flour for regional food exports and for industrial use. The investment enables Talian to scale up its operations and tap into the growing regional food markets and the premium industrial starch flour supply markets in East Africa.

(Logo: )

(Logo: )

Constrained by a lack of access to working capital and long-term debt finance, Talian has previously been unable to fully utilise its production capacity. By providing risk capital and technical support, AgDevCo’s investment increases Talian’s ability to purchase maize grain and cassava from over 6,500 smallholder farmers in Northern Uganda, for whom Talian provides higher and sustainable incomes.

This investment will strengthen the commercial cassava value-chain in Uganda where over 40% of production is now marketed commercially, following a revival in cassava production amongst small scale farmers in the country after years of neglect and disease challenges. Talian intends to grow into a significant player in the maize and cassava flour supply markets in East and Central Africa, in turn providing a market for grain and cassava farmers in Northern Uganda.

Francis Nyeko, founder and Managing Director of Talian, speaking at the close of the investment said:
For three years now, we have struggled to access sufficient working capital from the traditional financing system. The funding from AgDevCo opens the door for Talian to start fulfilling its potential to be a strong player in the local and regional industrial and food markets. We are delighted to work with an investor who understands the needs of SME businesses in Uganda.

Kim Kamarebe, AgDevCo Associate Director said:
This investment exemplifies AgDevCos commitment to filling the financing gap for SMEagribusinesses across Africa, and in doing so, providing a much-needed uplift to the incomes ofAfricas millions of smallholder farmersOur investment in Talian affords us the opportunity to demonstrate the impact of patient capital to SME businesses.


AgDevCo is a social impact investor incorporated in the UK, investing patient capital in the form of debt and equity into early-stage agribusinesses in sub-Saharan Africa with financial support from UKAid. AgDevCo’s mission is to reduce poverty and improve food security. AgDevCo has invested over USD 100 million in 57 agribusinesses to date, connecting over 240,000 farmers to markets and supporting over 7,600 jobs. In Uganda, AgDevCo is funded by the UK Government’s Department for International Development’s (DFID) NU-TEC programme.

For more information contact:
Kim Kamarebe
Associate Director, AgDevCo
tel: +256-200-923864


Call of Duty Documentary ‘CODumentary’ Releasing Worldwide by Devolver Digital Films September 19th, 2017

Feature-length documentation of a video game’s meteoric rise to global blockbuster status to release on major Digital platforms worldwide & DVD/Blu-Ray formats

Devolver Digital Films announces CODumentary, a documentary following a story centered about the blockbuster video game Call of Duty, releasing on digital platforms worldwide on Tuesday, September 19th at 10 AM PST.

The 93-minute feature documentary, created by Jonathan Beales, explores how the video game Call of Duty grew into a global entertainment blockbuster. Video game publisher/film distributor Devolver Digital will release the documentary worldwide on all major digital platforms on September 19th. DVD/Blu-Ray formats will be also be released.

“One of the biggest challenges was encapsulating a 15-year timeline into 93 minutes. I was fortunate to work with a lot of great people whose input & contribution helped make this happen. It’s a rich story of evolution told through the eyes of games developers, fans, industry experts and professional players.

It’s been a 5-year journey and even though the documentary is centered around video games, the story is always about the human input and endeavour. The rich experiences of developing games, playing them or waiting in line to buy them will always remain center stage,” said Producer Jonathan Beales.

Filmed across USA, UK & Europe including the D-Day beaches, CODumentary is told by developers, fans, professional players and numerous games experts, who describe in rich detail what makes the game so special and why it’s been successful from launch to the present day. Jonathan Beales is an industry professional with over 31 years’ experience in video games marketing & mainstream media.


Written, Directed and Produced by Jonathan Beales
UK/2017/93 min/HD
In English with sub-titles in 13 languages including German, French, Dutch, Italian, & Spanish.

CODumentary was independently produced by Jonathan Beales/Fizz Pictures, and is not a production of, affiliated with nor authorized by Activision Inc., Activision Publishing Inc.its affiliates, agents, or representatives. All gameplay and other related footage  appears in a commentary context and is protected by Fair Use doctrines. All Trademarks and copyrights fully recognized & acknowledged.

Related Links:       


Devolver Digital Films: 


SOURCE Devolver Digital Films

CONTACT: For more inquiries, photos, screeners, or to schedule an interview: Jonathan Beales, Producer/Director,, +447973-459693

Crystal River Cruises Christens Crystal Bach In Germany

Crystal River Cruises, the World’s Most Luxurious River Cruise Line™, christened Crystal Bach, the first of its four new build “Rhine Class” river ships, on Sunday, August 20 in Rüdesheim, Germany. Crystal’s CEO and president, Edie Rodriguez, presided over the ceremony, along with emcee and longtime popular Crystal entertainer, Mark Farris. The ship’s godmother, beloved German opera star Anna-Maria Kaufmann, christened the ship with the traditional blessing and champagne breaking, and also lent her famed talents to the celebration with a special performance of Johann Sebastian Bach’s “Air.” Also in attendance were the ship’s cruise guests, local travel partners and executives from Crystal’s parent company, Genting Hong Kong.

“The enthusiasm surrounding this groundbreaking ship has been tremendous already, and we could not be prouder to welcome her to the award-winning Crystal River fleet,” says Rodriguez. Addressing the crowd in attendance, she elaborated on the innovative approach to creating Crystal Bach and her upcoming sister ships. “The fact that she is Crystal’s first-ever new build river ship means that we had the opportunity to go beyond the best and create a luxury river cruise experience that is truly unprecedented. She is the first – and, until her sisters join her – the ONLY all-balcony, all-suite river ship.”

In another industry first, Crystal Bach and the “Rhine Class” ships feature all categories of accommodations positioned above the water line, boasting king-sized beds and Crystal’s acclaimed personal butler service. The design of the vessels firmly reiterates Crystal’s commitment to not only surpassing the very best the luxury travel industry currently has to offer, but leading the charge in pioneering new standards of luxury – a philosophy also driven home with the christening and debut of Crystal Skye, Crystal’s fully custom B-777, last week in Las Vegas.

“Crystal remains committed to being the standard bearer for what is possible in luxury travel, just as they have since they first embarked more than 27 years ago,” says Genting Hong Kong Chairman and CEO Tan Sri Lim Kok Thay. “We are proud to be part of and support this vision, and look forward to continuing on this journey together.”

The festivities of Crystal Bach’s christening reached far beyond those in attendance in Germany, as Crystal broadcast the live stream of the ceremony via its Crystal Cruises Facebook page, effectively inviting the world to join in the celebration.

Crystal Bach joins Crystal Mozart as part of the Crystal River Cruises fleet recently named “World’s Best River Cruise Line” by Travel + Leisure on Crystal Mozart’s one-year anniversary on July 11. Sailing 10- and 14-day voyages predominantly along the Rhine River, she will call in medieval towns and modern hubs in BelgiumNetherlandsSwitzerland and Germany.

All four “Rhine Class” river ships will offer plush amenities and spaces rare seen in the river cruising industry, including Panoramic Balcony-Windows™, walk-in closets and dual vanity in the bathrooms in most categories, ETRO robes and slippers, wall-mounted flat-screen HD TVs, and Nespresso machines. Additional enticing features include a luxurious spa and separate fitness center and Crystal’s farm-to-table, Michelin-inspired cuisine in multiple, open-seating eateries: the elegant Waterside Restaurant, namesake Bistro cafés and the exclusive Vintage Room; and the Palm Court.

By sea, river, land and air, Crystal has redefined the way the world views luxury travel. Celebrating 27 years of excellence, Crystal Cruises is the World’s Most Awarded Luxury Cruise Line, having earned “World’s Best Cruise Ship” in Condé Nast Traveler’s Reader Choice Awards for 23 years; been voted “World’s Best Large Ship Cruise Line” by Travel + Leisure readers for 20 years; and the “Best Luxury Cruise Line” by travel professional organization Virtuoso for three consecutive years (2014, 2015 & 2016).  The readers of Travel + Leisure also voted Crystal River Cruises the “World’s Best River Cruise Line” and Crystal Yacht Expedition Cruises the “World’s Best Small-Ship Cruise Line” in 2017. The newest and upcoming extensions of the celebrated Crystal brand include Crystal Yacht Expedition Cruises, Crystal Luxury Air, Crystal River Cruises – The World’s Most Luxurious River Cruise Line – Crystal AirCruises and Crystal Exclusive Class with Crystal Residences. Crystal is proud to be a platinum partner of the professionals of ASTA.

For more information and Crystal reservations, contact a travel agent, call 888.799.2437, or Join the hundreds of thousands who follow the Crystal Cruises’ Facebook page and @crystalcruises on Twitter and Instagram, and engage in the conversation with #crystalcruises.


Susan Robison

Prin Bacalan                 

Director, Global Public Relations

Finn Partners

(310) 203-4305


SOURCE Crystal River Cruises